1
|
Caramenti L, Gradowska PL, Moriña D, Byrnes G, Cardis E, Hauptmann M. Finite-Sample Bias of the Linear Excess Relative Risk in Cohort Studies of Computed Tomography-Related Radiation Exposure and Cancer. Radiat Res 2024; 201:206-214. [PMID: 38323646 DOI: 10.1667/rade-23-00187.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 01/22/2024] [Indexed: 02/08/2024]
Abstract
The linear excess relative risk (ERR) is the most commonly reported measure of association in radiation epidemiological studies, when individual dose estimates are available. While the asymptotic properties of the ERR estimator are well understood, there is evidence of small sample bias in case-control studies of treatment-related radiation exposure and second cancer risk. Cohort studies of cancer risk after exposure to low doses of radiation from diagnostic procedures, e.g., computed tomography (CT) examinations, typically have small numbers of cases and risks are small. Therefore, understanding the properties of the estimated ERR is essential for interpretation and analysis of such studies. We present results of a simulation study that evaluates the finite-sample bias of the ERR estimated by time-to-event analyses and its confidence interval using simulated data, resembling a retrospective cohort study of radiation-related leukemia risk after CT examinations in childhood and adolescence. Furthermore, we evaluate how the Firth-corrected estimator reduces the finite-sample bias of the classical estimator. We show that the ERR is overestimated by about 30% for a cohort of about 150,000 individuals, with 42 leukemia cases observed on average. The bias is reduced for higher baseline incidence rates and for higher values of the true ERR. As the number of cases increases, the ERR is approximately unbiased. The Firth correction reduces the bias for all cohort sizes to generally around or under 5%. Epidemiological studies showing an association between radiation exposure from pediatric CT and cancer risk, unless very large, may overestimate the magnitude of the relationship, while there is no evidence of an increased chance for false-positive results. Conducting large studies, perhaps by pooling individual studies to increase the number of cases, should be a priority. If this is not possible, Firth correction should be applied to reduce small-sample bias.
Collapse
Affiliation(s)
- L Caramenti
- Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane; Neuruppin, Germany
| | - P L Gradowska
- Erasmus MC Cancer Institute; Rotterdam, The Netherlands
| | - D Moriña
- Department of Econometrics, Statistics and Applied Economics, Riskcenter-IREA, Universitat de Barcelona (UB); Barcelona, Spain
| | - G Byrnes
- International Agency for Research in Cancer (IARC); Lyon, France
| | - E Cardis
- Institute for Global Health, ISGlobal; Barcelona, Spain
- Universitat Pompeu Fabra (UPF); Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP); Madrid, Spain
| | - M Hauptmann
- Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane; Neuruppin, Germany
| |
Collapse
|
2
|
Schüz J, Kovalevskiy E, Olsson A, Moissonnier M, Ostroumova E, Ferro G, Feletto E, Schonfeld SJ, Byrnes G, Tskhomariia I, Straif K, Morozova T, Kromhout H, Bukhtiyarov I. Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study). J Natl Cancer Inst 2024:djad262. [PMID: 38247448 DOI: 10.1093/jnci/djad262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/06/2023] [Accepted: 11/27/2023] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND We investigated mortality in workers of the world's largest chrysotile mine and enrichment factories located in the town of Asbest, Russian Federation. METHODS This historical cohort study included all workers employed for at least 1 year between 1975 and 2010 and follow-up until the end of 2015. Cumulative exposure to dust was estimated based on workers' complete occupational history linked to dust measurements systematically collected from the 1950s. Exposure to chrysotile fibers was estimated using dust-to-fiber conversion factors. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated as mortality rate ratios in Poisson regression models. RESULTS A total of 30 445 (32% women) workers accumulated 721 312 person-years at risk and 11 110 (36%) died. Of the workers, 54% had more than 30 years since their first exposure. We found an exposure-response between cumulative dust and lung cancer mortality in men. No clear association with dust exposure but a modest increase in the highest category of fiber exposure was seen for lung cancer in women. Mesothelioma mortality was increased (RR = 7.64, 95% CI = 1.18 to 49.5, to at least 80 fibers per cm3 years and RR = 4.56, 95% CI = 0.94 to 22.1, to at least 150 mg/m3 years [dust]), based on 13 deaths. For colorectal and stomach cancer, there were inconsistent associations. No associations were seen for laryngeal or ovarian cancer. CONCLUSION In this large-scale epidemiological study in the world's largest active asbestos mine, we confirmed an increased risk of mesothelioma with high fiber exposure and an increasing mortality for lung cancer in men with increasing dust exposure. Less clear-cut increased lung cancer mortality was seen in the women. Continued mortality follow-up is warranted.
Collapse
Affiliation(s)
- Joachim Schüz
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Evgeny Kovalevskiy
- Federal State Budgetary Scientific Institution, Izmerov Research Institute of Occupational Health, Moscow, Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Ann Olsson
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Monika Moissonnier
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Evgenia Ostroumova
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Gilles Ferro
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Eleonora Feletto
- International Agency for Research on Cancer-World Health Organization, Lyon, France
- The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council New South Wales, Sydney, Australia
| | - Sara J Schonfeld
- International Agency for Research on Cancer-World Health Organization, Lyon, France
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Graham Byrnes
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Iraklii Tskhomariia
- Federal State Budgetary Scientific Institution, Izmerov Research Institute of Occupational Health, Moscow, Russian Federation
| | - Kurt Straif
- International Agency for Research on Cancer-World Health Organization, Lyon, France
| | - Tatiana Morozova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Hans Kromhout
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands
| | - Igor Bukhtiyarov
- Federal State Budgetary Scientific Institution, Izmerov Research Institute of Occupational Health, Moscow, Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| |
Collapse
|
3
|
Bosch de Basea Gomez M, Thierry-Chef I, Harbron R, Hauptmann M, Byrnes G, Bernier MO, Le Cornet L, Dabin J, Ferro G, Istad TS, Jahnen A, Lee C, Maccia C, Malchair F, Olerud H, Simon SL, Figuerola J, Peiro A, Engels H, Johansen C, Blettner M, Kaijser M, Kjaerheim K, Berrington de Gonzalez A, Journy N, Meulepas JM, Moissonnier M, Nordenskjold A, Pokora R, Ronckers C, Schüz J, Kesminiene A, Cardis E. Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults. Nat Med 2023; 29:3111-3119. [PMID: 37946058 PMCID: PMC10719096 DOI: 10.1038/s41591-023-02620-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 09/29/2023] [Indexed: 11/12/2023]
Abstract
Over one million European children undergo computed tomography (CT) scans annually. Although moderate- to high-dose ionizing radiation exposure is an established risk factor for hematological malignancies, risks at CT examination dose levels remain uncertain. Here we followed up a multinational cohort (EPI-CT) of 948,174 individuals who underwent CT examinations before age 22 years in nine European countries. Radiation doses to the active bone marrow were estimated on the basis of body part scanned, patient characteristics, time period and inferred CT technical parameters. We found an association between cumulative dose and risk of all hematological malignancies, with an excess relative risk of 1.96 (95% confidence interval 1.10 to 3.12) per 100 mGy (790 cases). Similar estimates were obtained for lymphoid and myeloid malignancies. Results suggest that for every 10,000 children examined today (mean dose 8 mGy), 1-2 persons are expected to develop a hematological malignancy attributable to radiation exposure in the subsequent 12 years. Our results strengthen the body of evidence of increased cancer risk at low radiation doses and highlight the need for continued justification of pediatric CT examinations and optimization of doses.
Collapse
Affiliation(s)
- Magda Bosch de Basea Gomez
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabelle Thierry-Chef
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Richard Harbron
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Population Health Sciences Institute, Newcastle University, Newcastle-upon-Tyne, UK
| | - Michael Hauptmann
- Institute of Biostatistics and Registry Research, Brandenburg Medical School, Neuruppin, Germany
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Maria-Odile Bernier
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, France
| | - Lucian Le Cornet
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany
- German Cancer Research Center, Heidelberg, Germany
| | - Jérémie Dabin
- Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium
| | - Gilles Ferro
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Tore S Istad
- Norwegian Radiation and Nuclear Safety Authority, Oslo, Norway
| | - Andreas Jahnen
- Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Carlo Maccia
- Centre d'Assurance de qualité des Applications Technologiques dans le domaine de la Santé (CAATS), Sèvres, France
| | - Françoise Malchair
- Centre d'Assurance de qualité des Applications Technologiques dans le domaine de la Santé (CAATS), Sèvres, France
| | - Hilde Olerud
- Norwegian Radiation and Nuclear Safety Authority, Oslo, Norway
- Norwegian Radiation Protection Authority, Østerås, Norway
- University of South-Eastern Norway, Kongsberg, Norway
| | - Steven L Simon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Jordi Figuerola
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Anna Peiro
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Hilde Engels
- Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium
| | - Christoffer Johansen
- Cancer Late Effect Research Oncology Clinic (CASTLE), Center for Surgery and Cancer, Rigshospitalet, Copenhagen, Denmark
| | - Maria Blettner
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Magnus Kaijser
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | | | - Amy Berrington de Gonzalez
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
- Institute of Cancer Research, London, UK
| | - Neige Journy
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, France
- French National Institute of Health and Medical Research (INSERM) Unit 1018, Centre for Research in Epidemiology and Population Health, Paris Saclay University, Gustave Roussy, Villejuif, France
| | | | - Monika Moissonnier
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Arvid Nordenskjold
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - Roman Pokora
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Cecile Ronckers
- Institute of Biostatistics and Registry Research, Brandenburg Medical School, Neuruppin, Germany
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Ausrele Kesminiene
- International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France
| | - Elisabeth Cardis
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
- Pompeu Fabra University, Barcelona, Spain.
- Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
4
|
Zamora-Ros R, Cayssials V, Clèries R, Torrents M, Byrnes G, Weiderpass E, Sandström M, Almquist M, Boutron-Ruault MC, Tjønneland A, Kyrø C, Katzke VA, Le Cornet C, Masala G, Krogh V, Iannuzzo G, Tumino R, Milani L, Skeie G, Ubago-Guisado E, Amiano P, Chirlaque MD, Ardanaz E, Janzi S, Eriksson L, Freisling H, Heath AK, Rinaldi S, Agudo A. Sweetened beverages are associated with a higher risk of differentiated thyroid cancer in the EPIC cohort: a dietary pattern approach. Eur J Nutr 2023; 62:105-114. [PMID: 35907037 DOI: 10.1007/s00394-022-02953-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 07/05/2022] [Indexed: 02/07/2023]
Abstract
BACKGROUND Dietary pattern analysis has gained particular interest, because it reflects the complexity of dietary intake. The aim of this study was to explore the associations between a posteriori dietary patterns, derived using a data-driven approach, and the risk of differentiated thyroid cancer (TC) in Europe. METHODS This investigation included 450,064 adults from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Dietary intake was assessed using validated country-specific dietary questionnaires. A posteriori dietary patterns were computed using principal component analyses. Cox regression was used to calculate multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS After a mean follow-up time of 14 years, 712 first differentiated TCs were diagnosed. In the fully adjusted model, a dietary pattern characterized by alcohol consumption (basically beer and wine) was negatively associated with differentiated TC risk (HRQ4vs.Q1 = 0.75; 95% CI:0.60-0.94, P-trend = 0.005), while a dietary pattern rich in sweetened beverages was positively associated with differentiated TC risk (HRQ4vs.Q1 = 1.26; 95% CI:0.99-1.61; P-trend = 0.07). The remaining 8 dietary patterns were not related to differentiated TC risk. The intake of sweetened beverages was positively associated with differentiated TC risk (HR100mL/d = 1.05; 95% CI:1.00-1.11), especially with papillary TC risk (HR100mL/d = 1.07; 95% CI:1.01-1.13). Similar results were observed with sugary and artificially sweetened beverages. CONCLUSIONS The investigation of dietary patterns detected that the consumption of sweetened beverages was associated with a higher risk of differentiated thyroid cancer. Our results are in line with the general dietary recommendations of reducing the consumption of sweetened beverages.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- Unit of Nutrition and Cancer, Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona) , Av Gran Via 199-203, 08908, Barcelona, Spain.
| | - Valerie Cayssials
- Unit of Nutrition and Cancer, Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona) , Av Gran Via 199-203, 08908, Barcelona, Spain
- Department of Veterinary Public Health, Faculty of Veterinary, University of the Republic, Montevideo, Uruguay
- Department of Quantitative Methods, Faculty of Medicine, University of the Republic, Montevideo, Uruguay
| | - Ramon Clèries
- Pla Director d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona),, Barcelona, Spain
- Department of Clinical Sciences, University of Barcelona, Barcelona, Spain
| | - Maria Torrents
- Unit of Nutrition and Cancer, Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona) , Av Gran Via 199-203, 08908, Barcelona, Spain
| | - Graham Byrnes
- International Agency for Research On Cancer (IARC-WHO), Lyon, France
| | | | - Maria Sandström
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Martin Almquist
- Department of Surgery, Skåne University Hospital Malmö, Lund University, Lund, Sweden
| | - Marie-Christine Boutron-Ruault
- Centre for Research in Epidemiology and Population Health (CESP), Université Paris-Saclay, Université Paris-Sud, INSERM U1018, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Anne Tjønneland
- Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Cecilie Kyrø
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Verena A Katzke
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Charlotte Le Cornet
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Giovanna Masala
- Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Gabriella Iannuzzo
- Dipartimento Di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy
| | - Rosario Tumino
- AIRE - ONLUS, Hyblean Association for Epidemiological Research, Ragusa, Italy
| | - Lorenzo Milani
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Guri Skeie
- Department of Community Medicine, UiT the Arctic University of Norway, Tromsø, Norway
| | - Esther Ubago-Guisado
- Escuela Andaluza de Salud Pública (EASP), Granada, Spain
- Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Pilar Amiano
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, Biodonostia Health Research Institute, San Sebastian, Spain
| | - María-Dolores Chirlaque
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Department of Epidemiology, IMIB-Arrixaca, Murcia Regional Health Council, Murcia University, Murcia, Spain
| | - Eva Ardanaz
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Suzanne Janzi
- Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden
| | | | - Heinz Freisling
- International Agency for Research On Cancer (IARC-WHO), Lyon, France
| | - Alicia K Heath
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Sabina Rinaldi
- International Agency for Research On Cancer (IARC-WHO), Lyon, France
| | - Antonio Agudo
- Unit of Nutrition and Cancer, Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona) , Av Gran Via 199-203, 08908, Barcelona, Spain
| |
Collapse
|
5
|
Hauptmann M, Byrnes G, Cardis E, Bernier MO, Blettner M, Dabin J, Engels H, Istad TS, Johansen C, Kaijser M, Kjaerheim K, Journy N, Meulepas JM, Moissonnier M, Ronckers C, Thierry-Chef I, Le Cornet L, Jahnen A, Pokora R, Bosch de Basea M, Figuerola J, Maccia C, Nordenskjold A, Harbron RW, Lee C, Simon SL, Berrington de Gonzalez A, Schüz J, Kesminiene A. Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study. Lancet Oncol 2023; 24:45-53. [PMID: 36493793 DOI: 10.1016/s1470-2045(22)00655-6] [Citation(s) in RCA: 40] [Impact Index Per Article: 40.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 10/17/2022] [Accepted: 10/18/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND The European EPI-CT study aims to quantify cancer risks from CT examinations of children and young adults. Here, we assess the risk of brain cancer. METHODS We pooled data from nine European countries for this cohort study. Eligible participants had at least one CT examination before age 22 years documented between 1977 and 2014, had no previous diagnosis of cancer or benign brain tumour, and were alive and cancer-free at least 5 years after the first CT. Participants were identified through the Radiology Information System in 276 hospitals. Participants were linked with national or regional registries of cancer and vital status, and eligible cases were patients with brain cancers according to WHO International Classification of Diseases for Oncology. Gliomas were analysed separately to all brain cancers. Organ doses were reconstructed using historical machine settings and a large sample of CT images. Excess relative risks (ERRs) of brain cancer per 100 mGy of cumulative brain dose were calculated with linear dose-response modelling. The outcome was the first reported diagnosis of brain cancer after an exclusion period of 5 years after the first electronically recorded CT examination. FINDINGS We identified 948 174 individuals, of whom 658 752 (69%) were eligible for our study. 368 721 (56%) of 658 752 participants were male and 290 031 (44%) were female. During a median follow-up of 5·6 years (IQR 2·4-10·1), 165 brain cancers occurred, including 121 (73%) gliomas. Mean cumulative brain dose, lagged by 5 years, was 47·4 mGy (SD 60·9) among all individuals and 76·0 mGy (100·1) among people with brain cancer. A significant linear dose-response relationship was observed for all brain cancers (ERR per 100 mGy 1·27 [95% CI 0·51-2·69]) and for gliomas separately (ERR per 100 mGy 1·11 [0·36-2·59]). Results were robust when the start of follow-up was delayed beyond 5 years and when participants with possibly previously unreported cancers were excluded. INTERPRETATION The observed significant dose-response relationship between CT-related radiation exposure and brain cancer in this large, multicentre study with individual dose evaluation emphasises careful justification of paediatric CTs and use of doses as low as reasonably possible. FUNDING EU FP7; Belgian Cancer Registry; La Ligue contre le Cancer, L'Institut National du Cancer, France; Ministry of Health, Labour and Welfare of Japan; German Federal Ministry of Education and Research; Worldwide Cancer Research; Dutch Cancer Society; Research Council of Norway; Consejo de Seguridad Nuclear, Generalitat de Catalunya, Spain; US National Cancer Institute; UK National Institute for Health Research; Public Health England.
Collapse
Affiliation(s)
- Michael Hauptmann
- Institute of Biostatistics and Registry Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School, Neuruppin, Germany.
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC/WHO), Environmental and Lifestyle Epidemiology Branch, Lyon, France
| | - Elisabeth Cardis
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Marie-Odile Bernier
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, France
| | - Maria Blettner
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Jérémie Dabin
- Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium
| | - Hilde Engels
- Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium
| | - Tore S Istad
- Norwegian Radiation and Nuclear Safety Authority, Oslo, Norway
| | - Christoffer Johansen
- Cancer Late Effect Research Oncology Clinic (CASTLE), Center for Surgery and Cancer, Rigshospitalet, Copenhagen, Denmark
| | - Magnus Kaijser
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | | | - Neige Journy
- Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux Roses, France; French National Institute of Health and Medical Research (Inserm), U1018, Centre for Research in Epidemiology and Population Health (CESP), Radiation Epidemiology Group, Gustave Roussy, Paris-Saclay, Paris-Sud University, Gustave Roussy, Villejuif, France
| | | | - Monika Moissonnier
- International Agency for Research on Cancer (IARC/WHO), Environmental and Lifestyle Epidemiology Branch, Lyon, France
| | - Cecile Ronckers
- Institute of Biostatistics and Registry Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School, Neuruppin, Germany
| | - Isabelle Thierry-Chef
- International Agency for Research on Cancer (IARC/WHO), Environmental and Lifestyle Epidemiology Branch, Lyon, France; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Lucian Le Cornet
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; German Cancer Research Center, Heidelberg, Germany
| | - Andreas Jahnen
- Luxembourg Institute of Science and Technology (LIST), Esch-sur-Alzette, Luxembourg
| | - Roman Pokora
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Magda Bosch de Basea
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Jordi Figuerola
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Carlo Maccia
- CAATS, Centre d'Assurance de qualité des Applications Technologiques dans le domaine de la Santé, Sèvres, France
| | - Arvid Nordenskjold
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - Richard W Harbron
- Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Steven L Simon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Amy Berrington de Gonzalez
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO), Environmental and Lifestyle Epidemiology Branch, Lyon, France
| | - Ausrele Kesminiene
- International Agency for Research on Cancer (IARC/WHO), Environmental and Lifestyle Epidemiology Branch, Lyon, France
| |
Collapse
|
6
|
Thierry-Chef I, Ferro G, Le Cornet L, Dabin J, Istad TS, Jahnen A, Lee C, Maccia C, Malchair F, Olerud HM, Harbron RW, Figuerola J, Hermen J, Moissonnier M, Bernier MO, Bosch de Basea MB, Byrnes G, Cardis E, Hauptmann M, Journy N, Kesminiene A, Meulepas JM, Pokora R, Simon SL. Dose Estimation for the European Epidemiological Study on Pediatric Computed Tomography (EPI-CT). Radiat Res 2021; 196:74-99. [PMID: 33914893 DOI: 10.1667/rade-20-00231.1] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 03/26/2021] [Indexed: 11/03/2022]
Abstract
Within the European Epidemiological Study to Quantify Risks for Paediatric Computerized Tomography (EPI-CT study), a cohort was assembled comprising nearly one million children, adolescents and young adults who received over 1.4 million computed tomography (CT) examinations before 22 years of age in nine European countries from the late 1970s to 2014. Here we describe the methods used for, and the results of, organ dose estimations from CT scanning for the EPI-CT cohort members. Data on CT machine settings were obtained from national surveys, questionnaire data, and the Digital Imaging and Communications in Medicine (DICOM) headers of 437,249 individual CT scans. Exposure characteristics were reconstructed for patients within specific age groups who received scans of the same body region, based on categories of machines with common technology used over the time period in each of the 276 participating hospitals. A carefully designed method for assessing uncertainty combined with the National Cancer Institute Dosimetry System for CT (NCICT, a CT organ dose calculator), was employed to estimate absorbed dose to individual organs for each CT scan received. The two-dimensional Monte Carlo sampling method, which maintains a separation of shared and unshared error, allowed us to characterize uncertainty both on individual doses as well as for the entire cohort dose distribution. Provided here are summaries of estimated doses from CT imaging per scan and per examination, as well as the overall distribution of estimated doses in the cohort. Doses are provided for five selected tissues (active bone marrow, brain, eye lens, thyroid and female breasts), by body region (i.e., head, chest, abdomen/pelvis), patient age, and time period (1977-1990, 1991-2000, 2001-2014). Relatively high doses were received by the brain from head CTs in the early 1990s, with individual mean doses (mean of 200 simulated values) of up to 66 mGy per scan. Optimization strategies implemented since the late 1990s have resulted in an overall decrease in doses over time, especially at young ages. In chest CTs, active bone marrow doses dropped from over 15 mGy prior to 1991 to approximately 5 mGy per scan after 2001. Our findings illustrate patterns of age-specific doses and their temporal changes, and provide suitable dose estimates for radiation-induced risk estimation in epidemiological studies.
Collapse
Affiliation(s)
- Isabelle Thierry-Chef
- International Agency for Research on Cancer, Lyon, France
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Gilles Ferro
- International Agency for Research on Cancer, Lyon, France
| | - Lucian Le Cornet
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany
- German Cancer Research Center, Heidelberg, Germany
| | - Jérémie Dabin
- Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium
| | - Tore S Istad
- Norwegian Radiation and Nuclear Safety Authority, NO-0213 Oslo, Norway
| | - Andreas Jahnen
- Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | | | | | - Hilde M Olerud
- University of South-Eastern Norway, Faculty of Health and Social Sciences, Kongsberg, Norway
| | - Richard W Harbron
- Institute of Health and Society, Newcastle University (UNEW), Newcastle upon Tyne, United Kingdom
- NIHR Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Newcastle University, United Kingdom
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Jordi Figuerola
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Johannes Hermen
- Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg
| | | | - Marie-Odile Bernier
- Institut de Radioprotection et de Sûreté Nucléaire, Laboratoire d'épidémiologie des Rayonnements Ionisants, Fontenay-aux-Roses, France
| | - Magda Bosch Bosch de Basea
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - Elisabeth Cardis
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Michael Hauptmann
- Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands
- Institute of BiostatisTics and Registry Research, Medical University Brandenburg Theodor Fontane, Neuruppin, Germany
| | - Neige Journy
- Institut de Radioprotection et de Sûreté Nucléaire, Laboratoire d'épidémiologie des Rayonnements Ionisants, Fontenay-aux-Roses, France
- French National Institute of Health and Medical Research (Inserm) Unit 1018, Centre for Research in Epidemiology and Population Health (CESP), Cancer and Radiations Group, Gustave Roussy, Villejuif, France
| | | | - Johanna M Meulepas
- Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Roman Pokora
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany
| | - Steven L Simon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland
| |
Collapse
|
7
|
Zamora-Ros R, Lujan-Barroso L, Achaintre D, Franceschi S, Kyrø C, Overvad K, Tjønneland A, Truong T, Lecuyer L, Boutron-Ruault MC, Katzke V, Johnson TS, Schulze MB, Trichopoulou A, Peppa E, La Vechia C, Masala G, Pala V, Panico S, Tumino R, Ricceri F, Skeie G, Quirós JR, Rodriguez-Barranco M, Amiano P, Chirlaque MD, Ardanaz E, Almquist M, Hennings J, Vermeulen R, Wareham NJ, Tong TYN, Aune D, Byrnes G, Weiderpass E, Scalbert A, Rinaldi S, Agudo A. Blood polyphenol concentrations and differentiated thyroid carcinoma in women from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 2021; 113:162-171. [PMID: 33021645 PMCID: PMC7779226 DOI: 10.1093/ajcn/nqaa277] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 09/07/2020] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Polyphenols are natural compounds with anticarcinogenic properties in cellular and animal models, but epidemiological evidence determining the associations of these compounds with thyroid cancer (TC) is lacking. OBJECTIVES The aim of this study was to evaluate the relations between blood concentrations of 36 polyphenols and TC risk in EPIC (the European Prospective Investigation into Cancer and Nutrition). METHODS A nested case-control study was conducted on 273 female cases (210 papillary, 45 follicular, and 18 not otherwise specified TC tumors) and 512 strictly matched controls. Blood polyphenol concentrations were analyzed by HPLC coupled to tandem MS after enzymatic hydrolysis. RESULTS Using multivariable-adjusted conditional logistic regression models, caffeic acid (ORlog2: 0.55; 95% CI: 0.33, 0.93) and its dehydrogenated metabolite, 3,4-dihydroxyphenylpropionic acid (ORlog2: 0.84; 95% CI: 0.71, 0.99), were inversely associated with differentiated TC risk. Similar results were observed for papillary TC, but not for follicular TC. Ferulic acid was also inversely associated only with papillary TC (ORlog2: 0.68; 95% CI: 0.51, 0.91). However, none of these relations was significant after Bonferroni correction for multiple testing. No association was observed for any of the remaining polyphenols with total differentiated, papillary, or follicular TC. CONCLUSIONS Blood polyphenol concentrations were mostly not associated with differentiated TC risk in women, although our study raises the possibility that high blood concentrations of caffeic, 3,4-dihydroxyphenylpropionic, and ferulic acids may be related to a lower papillary TC risk.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - Leila Lujan-Barroso
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - David Achaintre
- International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Silvia Franceschi
- Oncology Referral Center (CRO), Aviano National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy
| | - Cecilie Kyrø
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kim Overvad
- Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Anne Tjønneland
- Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Therese Truong
- Versailles Saint-Quentin-en-Yvelines University (UVSQ), Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France
- Gustave Roussy, Villejuif, France
| | - Lucie Lecuyer
- Versailles Saint-Quentin-en-Yvelines University (UVSQ), Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France
- Gustave Roussy, Villejuif, France
| | - Marie-Christine Boutron-Ruault
- Versailles Saint-Quentin-en-Yvelines University (UVSQ), Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France
- Gustave Roussy, Villejuif, France
| | - Verena Katzke
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Theron S Johnson
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Matthias B Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
- Institute of Nutritional Sciences, University of Potsdam, Nuthetal, Germany
| | | | | | - Carlo La Vechia
- Hellenic Health Foundation, Athens, Greece
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Giovanna Masala
- Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network—ISPRO, Florence, Italy
| | - Valeria Pala
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Department, “Civic—MP Arezzo” Hospital, ASP Ragusa, Ragusa, Italy
| | - Fulvio Ricceri
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
- Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco, Turin, Italy
| | - Guri Skeie
- Department of Community Medicine, UiT the Arctic University of Norway, Tromsø, Norway
| | | | - Miguel Rodriguez-Barranco
- Andalusian School of Public Health, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
| | - Pilar Amiano
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain
| | - María-Dolores Chirlaque
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, Spain
| | - Eva Ardanaz
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Martin Almquist
- Department of Surgery, Endocrine-Sarcoma Unit, Skåne University Hospital, Lund, Sweden
| | - Joakim Hennings
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - Roel Vermeulen
- Institute of Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands
- Department of Public Health, University Medical Center Utrecht, Utrecht, Netherlands
| | - Nicholas J Wareham
- Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Tammy Y N Tong
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Dagfinn Aune
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Department of Nutrition, Bjørknes University College, Oslo, Norway
- Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | | | - Augustin Scalbert
- International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Sabina Rinaldi
- International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| |
Collapse
|
8
|
Hosen MI, Forey N, Durand G, Voegele C, Bilici S, Avogbe PH, Delhomme TM, Foll M, Manel A, Vian E, Meziani S, De Tilly B, Polo G, Lole O, Francois P, Boureille A, Pisarev E, Salas AROSE, Monteiro-Reis S, Henrique R, Byrnes G, Jeronimo C, Scelo G, McKay JD, Calvez-Kelm FL, Zvereva M. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. Cancers (Basel) 2020; 12:E3541. [PMID: 33260905 PMCID: PMC7761513 DOI: 10.3390/cancers12123541] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 11/18/2020] [Accepted: 11/23/2020] [Indexed: 12/24/2022] Open
Abstract
Somatic mutations in the telomerase reverse transcriptase (TERT) promoter regions are frequent events in urothelial cancer (UC) and their detection in urine (supernatant cell-free DNA or DNA from exfoliated cells) could serve as putative non-invasive biomarkers for UC detection and monitoring. However, detecting these tumor-borne mutations in urine requires highly sensitive methods, capable of measuring low-level mutations. In this study, we developed sensitive droplet digital PCR (ddPCR) assays for detecting TERT promoter mutations (C228T, C228A, CC242-243TT, and C250T). We tested the C228T and C250T ddPCR assays on all samples with sufficient quantity of urinary DNA (urine supernatant cell-free DNA (US cfDNA) or urine pellet cellular DNA (UP cellDNA)) from the DIAGURO (n = 89/93 cases and n = 92/94 controls) and from the IPO-PORTO (n = 49/50 cases and n = 50/50 controls) series that were previously screened with the UroMuTERT assay and compared the performance of the two approaches. In the DIAGURO series, the sensitivity and specificity of the ddPCR assays for detecting UC using either US cfDNA or UP cellDNA were 86.8% and 92.4%. The sensitivity was slightly higher than that of the UroMuTERT assay in the IPO-PORTO series (67.4% vs. 65.3%, respectively), but not in the DIAGURO series (86.8% vs. 90.7%). The specificity was 100% in the IPO-PORTO controls for both the UroMuTERT and ddPCR assays, whereas in the DIAGURO series, the specificity dropped for ddPCR (92.4% versus 95.6%). Overall, an almost perfect agreement between the two methods was observed for both US cfDNA (n = 164; kappa coefficient of 0.91) and UP cellDNA (n = 280; kappa coefficient of 0.94). In a large independent series of serial urine samples from DIAGURO follow-up BC cases (n = 394), the agreement between ddPCR and UroMuTERT was (i) strong (kappa coefficient of 0.87), regardless of urine DNA types (kappa coefficient 0.89 for US cfDNA and 0.85 for UP cellDNA), (ii) the highest for samples with mutant allelic fractions (MAFs) > 2% (kappa coefficient of 0.99) and (iii) only minimal for the samples with the lowest MAFs (< 0.5%; kappa coefficient 0.32). Altogether, our results indicate that the two methods (ddPCR and UroMuTERT) for detecting urinary TERT promoter mutations are comparable and that the discrepancies relate to the detection of low-allelic fraction mutations. The simplicity of the ddPCR assays makes them suitable for implementation in clinical settings.
Collapse
Affiliation(s)
- Md Ismail Hosen
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
- Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Dhaka, Dhaka 1000, Bangladesh
| | - Nathalie Forey
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Geoffroy Durand
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Catherine Voegele
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Selin Bilici
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Patrice Hodonou Avogbe
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Tiffany Myriam Delhomme
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Matthieu Foll
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | | | - Emmanuel Vian
- Department of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France; (E.V.); (B.D.T.); (G.P.)
| | - Sonia Meziani
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Berengere De Tilly
- Department of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France; (E.V.); (B.D.T.); (G.P.)
| | - Gilles Polo
- Department of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France; (E.V.); (B.D.T.); (G.P.)
| | - Olesia Lole
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Pauline Francois
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Antoine Boureille
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Eduard Pisarev
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia;
| | - Andrei R. O. S. E. Salas
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
- Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo 01221-020, Brazil
| | - Sara Monteiro-Reis
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal; (S.M.-R.); (R.H.); (C.J.)
| | - Rui Henrique
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal; (S.M.-R.); (R.H.); (C.J.)
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4099-002 Porto, Portugal
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Carmen Jeronimo
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal; (S.M.-R.); (R.H.); (C.J.)
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal
- Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4099-002 Porto, Portugal
| | - Ghislaine Scelo
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
- Department of Medical Sciences, University of Turin, 8-10124 Turin, Italy
| | - James D. McKay
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Florence Le Calvez-Kelm
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
| | - Maria Zvereva
- International Agency for Research on Cancer (IARC), 69372 Lyon, France; (M.I.H.); (N.F.); (G.D.); (C.V.); (S.B.); (P.H.A.); (T.M.D.); (M.F.); (S.M.); (O.L.); (P.F.); (A.B.); (A.R.O.S.E.S.); (G.B.); (G.S.); (J.D.M.)
- Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia
| |
Collapse
|
9
|
Olsson A, Kovalevskiy EV, Talibov M, Moissonnier M, Byrnes G, Bouaoun L, Schonfeld SJ, Feletto E, Kashanskiy SV, Ostroumova E, Kromhout H, Bukhtiyarov IV, Schüz J. Tobacco smoking among chrysotile asbestos workers in Asbest in the Russian Federation. Occup Environ Med 2020; 77:623-627. [PMID: 32398292 PMCID: PMC7476310 DOI: 10.1136/oemed-2019-106263] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 02/24/2020] [Accepted: 04/18/2020] [Indexed: 11/04/2022]
Abstract
OBJECTIVES A historical cohort study of cancer mortality is being conducted among workers in a chrysotile mine and its enrichment factories in the town of Asbest, Russian Federation. Because individual-level information on tobacco use is not available for Asbest Chrysotile Cohort members, a cross-sectional survey of smoking behaviours was conducted among active and retired workers. METHODS Self-administered questionnaires were completed by active workers during meetings organised by occupational safety personnel. Retired workers completed questionnaires during meetings of the Veterans Council or were interviewed via telephone or in person. Of the respondents, 46% could be linked to the Asbest Chrysotile Cohort. Among those, logistic regression models were used to assess associations between smoking and cumulative dust exposure. RESULTS Among men, smoking prevalence was high and relatively consistent across birth decades (average, 66%), and was similar in workers across all levels of cumulative dust exposure (p trend, 0.44). Among women, the prevalence increased from <10% in those born before 1960 to 30% in those born after 1980, and smoking was associated with exposure to dust versus not exposed to dust (p value, 0.006), but did not vary appreciably across workers in different cumulative dust exposure categories (p trend, 0.29). CONCLUSIONS Our study suggests that cross-sectional surveys may be a useful tool for understanding the potential health impact from smoking in occupational cohorts, including possible confounding by smoking. This survey showed that adjustment at the age group level among women is needed to reduce residual confounding and account for smoking patterns, which have changed substantially over time.
Collapse
Affiliation(s)
- Ann Olsson
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Evgeny V Kovalevskiy
- Federal State Budgetary Scientific Institution "Izmerov Research Institute of Occupational Health", Moscow, Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Madar Talibov
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Monika Moissonnier
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Liacine Bouaoun
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Sara J Schonfeld
- Radiation Epidemiology Branch, National Cancer Institute Division of Cancer Epidemiology and Genetics, Bethesda, Maryland, USA
| | - Eleonora Feletto
- Cancer Research Division, Cancer Council New South Wales, Woolloomooloo, New South Wales, Australia
- School of Public Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Sergey V Kashanskiy
- Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers, Yekaterinburg, Russian Federation
| | - Evgenia Ostroumova
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Hans Kromhout
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Igor V Bukhtiyarov
- Federal State Budgetary Scientific Institution "Izmerov Research Institute of Occupational Health", Moscow, Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Joachim Schüz
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
10
|
Schüz J, Bukhtiyarov I, Olsson A, Moissonnier M, Ostroumova E, Feletto E, Schonfeld SJ, Byrnes G, Tskhomariia I, McCormack V, Straif K, Kashanskiy S, Morozova T, Kromhout H, Kovalevskiy E. Occupational cohort study of current and former workers exposed to chrysotile in mine and processing facilities in Asbest, the Russian Federation: Cohort profile of the Asbest Chrysotile Cohort study. PLoS One 2020; 15:e0236475. [PMID: 32726334 PMCID: PMC7390538 DOI: 10.1371/journal.pone.0236475] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 07/03/2020] [Indexed: 02/04/2023] Open
Abstract
A historical cohort study in workers occupationally exposed to chrysotile was set up in the town of Asbest, the Russian Federation, to study their cause-specific mortality, with a focus on cancer. Chrysotile has different chemical and physical properties compared with other asbestos fibres; therefore it is important to conduct studies specifically of chrysotile and in different geographical regions to improve the knowledge about its carcinogenicity. Setting was the town of Asbest, Sverdlovsk oblast, the Russian Federation. Participants were all current and former employees with at least one year of employment between 1/1/1975 and 31/12/2010 in the mine, enrichment factories, auto-transport and external rail transportation departments, the central laboratory, and the explosives unit of the company. Of the 35,837 cohort members, 12,729 (35.5%) had died (2,373 of them of cancer, including 10 of mesothelioma), 18,799 (52.5%) were known to be alive at the end of the observation period (2015), and 4,309 (12.0%) were censored before the end of 2015. Mean follow-up duration was 21.7 years in men and 25.9 years in women. The mean age at death was 59.4 years in men and 66.5 years in women. This is the largest occupational cohort of chrysotile workers to date, and the only one with a large proportion of exposed female workers.
Collapse
Affiliation(s)
- Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Igor Bukhtiyarov
- Federal State Budgetary Scientific Institution “Izmerov Research Institute of Occupational Health” (IRIOH), Moscow, the Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, the Russian Federation
| | - Ann Olsson
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | | | | | - Eleonora Feletto
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
- Cancer Council New South Wales, Cancer Research Division, Woolloomooloo, Australia
| | - Sara J Schonfeld
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Iraklii Tskhomariia
- Federal State Budgetary Scientific Institution “Izmerov Research Institute of Occupational Health” (IRIOH), Moscow, the Russian Federation
| | - Valerie McCormack
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Kurt Straif
- International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Sergey Kashanskiy
- Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers, Yekaterinburg, the Russian Federation
| | - Tatiana Morozova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, the Russian Federation
| | - Hans Kromhout
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Evgeny Kovalevskiy
- Federal State Budgetary Scientific Institution “Izmerov Research Institute of Occupational Health” (IRIOH), Moscow, the Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, the Russian Federation
| |
Collapse
|
11
|
Delhomme TM, Avogbe PH, Gabriel AAG, Alcala N, Leblay N, Voegele C, Vallée M, Chopard P, Chabrier A, Abedi-Ardekani B, Gaborieau V, Holcatova I, Janout V, Foretová L, Milosavljevic S, Zaridze D, Mukeriya A, Brambilla E, Brennan P, Scelo G, Fernandez-Cuesta L, Byrnes G, Calvez-Kelm FL, McKay JD, Foll M. Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data. NAR Genom Bioinform 2020; 2:lqaa021. [PMID: 32363341 PMCID: PMC7182099 DOI: 10.1093/nargab/lqaa021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 01/28/2020] [Accepted: 04/16/2020] [Indexed: 12/22/2022] Open
Abstract
The emergence of next-generation sequencing (NGS) has revolutionized the way of reaching a genome sequence, with the promise of potentially providing a comprehensive characterization of DNA variations. Nevertheless, detecting somatic mutations is still a difficult problem, in particular when trying to identify low abundance mutations, such as subclonal mutations, tumour-derived alterations in body fluids or somatic mutations from histological normal tissue. The main challenge is to precisely distinguish between sequencing artefacts and true mutations, particularly when the latter are so rare they reach similar abundance levels as artefacts. Here, we present needlestack, a highly sensitive variant caller, which directly learns from the data the level of systematic sequencing errors to accurately call mutations. Needlestack is based on the idea that the sequencing error rate can be dynamically estimated from analysing multiple samples together. We show that the sequencing error rate varies across alterations, illustrating the need to precisely estimate it. We evaluate the performance of needlestack for various types of variations, and we show that needlestack is robust among positions and outperforms existing state-of-the-art method for low abundance mutations. Needlestack, along with its source code is freely available on the GitHub platform: https://github.com/IARCbioinfo/needlestack.
Collapse
Affiliation(s)
- Tiffany M Delhomme
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Patrice H Avogbe
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Aurélie A G Gabriel
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Nicolas Alcala
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Noemie Leblay
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Catherine Voegele
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Maxime Vallée
- Genetic Epidemiology Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Priscilia Chopard
- Genetic Epidemiology Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Amélie Chabrier
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Behnoush Abedi-Ardekani
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Valérie Gaborieau
- Genetic Epidemiology Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Ivana Holcatova
- Institute of Hygiene and Epidemiology, Charles University, 1st Faculty of Medicine, 116 36 Prague, Czech Republic
| | - Vladimir Janout
- Faculty of Health Sciences, Palacky University, 775 15 Olomouc, Czech Republic
| | - Lenka Foretová
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
| | - Sasa Milosavljevic
- International Organization for Cancer Prevention and Research (IOCPR), 11070 Belgrade, Serbia
| | - David Zaridze
- Russian N.N. Blokhin Cancer Research Centre, 115478 Moscow, The Russian Federation
| | - Anush Mukeriya
- Russian N.N. Blokhin Cancer Research Centre, 115478 Moscow, The Russian Federation
| | - Elisabeth Brambilla
- Centre Hospitalier Universitaire de Grenoble Département d’Anatomie et Cytologie Pathologiques, CS 10217 38043 Grenoble, France
| | - Paul Brennan
- Genetic Epidemiology Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Ghislaine Scelo
- Genetic Epidemiology Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Lynnette Fernandez-Cuesta
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Florence L Calvez-Kelm
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - James D McKay
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| | - Matthieu Foll
- Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France
| |
Collapse
|
12
|
Zamora-Ros R, Cayssials V, Franceschi S, Kyrø C, Weiderpass E, Hennings J, Sandström M, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Truong T, Mancini FR, Katzke V, Kühn T, Boeing H, Trichopoulou A, Karakatsani A, Martimianaki G, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Lasheras C, Rodríguez-Barranco M, Amiano P, Colorado-Yohar SM, Ardanaz E, Almquist M, Ericson U, Bueno-de-Mesquita HB, Vermeulen R, Schmidt JA, Byrnes G, Scalbert A, Agudo A, Rinaldi S. Polyphenol intake and differentiated thyroid cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer 2020; 146:1841-1850. [PMID: 31342519 DOI: 10.1002/ijc.32589] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 05/30/2019] [Accepted: 06/18/2019] [Indexed: 12/30/2022]
Abstract
Polyphenols are bioactive compounds with several anticarcinogenic activities; however, human data regarding associations with thyroid cancer (TC) is still negligible. Our aim was to evaluate the association between intakes of total, classes and subclasses of polyphenols and risk of differentiated TC and its main subtypes, papillary and follicular, in a European population. The European Prospective Investigation into Cancer and Nutrition cohort included 476,108 men and women from 10 European countries. During a mean follow-up of 14 years, there were 748 incident differentiated TC cases, including 601 papillary and 109 follicular tumors. Polyphenol intake was estimated at baseline using validated center/country-specific dietary questionnaires and the Phenol-Explorer database. In multivariable-adjusted Cox regression models, no association between total polyphenol and the risks of overall differentiated TC (HRQ4 vs. Q1 = 0.99, 95% confidence interval [CI] 0.77-1.29), papillary (HRQ4 vs. Q1 = 1.06, 95% CI 0.80-1.41) or follicular TC (HRQ4 vs. Q1 = 1.10, 95% CI 0.55-2.22) were found. No associations were observed either for flavonoids, phenolic acids or the rest of classes and subclasses of polyphenols. After stratification by body mass index (BMI), an inverse association between the intake of polyphenols (p-trend = 0.019) and phenolic acids (p-trend = 0.007) and differentiated TC risk in subjects with BMI ≥ 25 was observed. In conclusion, our study showed no associations between dietary polyphenol intake and differentiated TC risk; although further studies are warranted to investigate the potential protective associations in overweight and obese individuals.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - Valerie Cayssials
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- Departamento de Bioestadística, Facultad de Veterinaria, Universidad de la República, Montevideo, Uruguay
| | | | - Cecilie Kyrø
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | | | - Joakim Hennings
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - Maria Sandström
- Department for Radiation Sciences, Umeå University, Umeå, Sweden
| | - Anne Tjønneland
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Anja Olsen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kim Overvad
- Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
| | - Marie-Christine Boutron-Ruault
- CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Thérèse Truong
- INSERM, Center for Research in Epidemiology and Population Health (CESP), Cancer and Environment Team, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Francesca Romana Mancini
- CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Verena Katzke
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | | | - Anna Karakatsani
- Hellenic Health Foundation, Athens, Greece
- 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece
| | | | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
| | - Vittorio Krogh
- Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Salvatore Panico
- Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, "Civic M.P. Arezzo" Hospital, ASP, Ragusa, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
| | - Cristina Lasheras
- Department of Functional Biology, Faculty of Medicine. University of Oviedo, Oviedo, Spain
| | - Miguel Rodríguez-Barranco
- Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs. GRANADA, Universidad de Granada, Granada, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Pilar Amiano
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Sandra M Colorado-Yohar
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
- Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia
| | - Eva Ardanaz
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Martin Almquist
- Department of Surgery, Skåne University Hospital Malmö, Lund University, Lund, Sweden
| | - Ulrika Ericson
- Diabetes and Cardiovascular disease, Genetic Epidemiology, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - H Bas Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom
- Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Roel Vermeulen
- Institute of Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
- Department of Public Health, the University Medical Center Utrecht, Utrecht, The Netherlands
| | - Julie A Schmidt
- Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - Sabina Rinaldi
- International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
13
|
Middleton DRS, Xie SH, Bouaoun L, Byrnes G, Song GH, Schüz J, Wei WQ, McCormack VA. Esophageal Thermal Exposure to Hot Beverages: A Comparison of Metrics to Discriminate Distinct Consumption Habits. Cancer Epidemiol Biomarkers Prev 2019; 28:2005-2013. [PMID: 31558508 DOI: 10.1158/1055-9965.epi-19-0856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 08/28/2019] [Accepted: 09/17/2019] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Hot beverage consumption is a probable risk factor for esophageal squamous cell carcinoma (ESCC). No standardized exposure assessment protocol exists. METHODS To compare how alternative metrics discriminate distinct drinking habits, we measured sip temperatures and sizes in an international group of hot beverage drinkers in France (n = 20) and hot porridge consumers (n = 52) in a high ESCC incidence region of China. Building on the knowledge that sip size and temperature affect intraesophageal liquid temperature (IELT), IELTs were predicted by modeling existing data, and compared with first sip temperature and, across all sips, mean temperature and sip-weighted mean temperature. RESULTS Two contrasting exposure characteristics were observed. Compared with the international group, Chinese porridge consumers took larger first sips [mean difference +17 g; 95% confidence interval (CI), 13.3-20.7] of hotter (+9.5°C; 95% CI, 6.2-12.7) liquid, and their mean sip size did not vary greatly across sips, but the former groups increased in size as temperature decreased. This resulted in higher predicted IELTs (mean 61°C vs. 42.4°C) and sip-weighted temperatures (76.9°C vs. 56°C) in Chinese porridge consumers, and compared with first sip and mean temperature, these two metrics separated the groups to a greater extent. CONCLUSIONS Distinguishing thermal exposure characteristics between these groups was greatly enhanced by measuring sip sizes. Temperature at first sip alone is suboptimal for assessing human exposure to hot foods and beverages, and future studies should include sip size measurements in exposure assessment protocols. IMPACT This study provides a logistically feasible framework for assessing human exposure to hot beverages.
Collapse
Affiliation(s)
- Daniel R S Middleton
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France.
| | - Shuang-Hua Xie
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Liacine Bouaoun
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Guo-Hui Song
- Cancer Institute/Hospital of Ci County, Cixian, China
| | - Joachim Schüz
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| | - Wen-Qiang Wei
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| | - Valerie A McCormack
- Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
14
|
Zamora-Ros R, Alghamdi MA, Cayssials V, Franceschi S, Almquist M, Hennings J, Sandström M, Tsilidis KK, Weiderpass E, Boutron-Ruault MC, Hammer Bech B, Overvad K, Tjønneland A, Petersen KEN, Mancini FR, Mahamat-Saleh Y, Bonnet F, Kühn T, Fortner RT, Boeing H, Trichopoulou A, Bamia C, Martimianaki G, Masala G, Grioni S, Panico S, Tumino R, Fasanelli F, Skeie G, Braaten T, Lasheras C, Salamanca-Fernández E, Amiano P, Chirlaque MD, Barricarte A, Manjer J, Wallström P, Bueno-de-Mesquita HB, Peeters PH, Khaw KT, Wareham NJ, Schmidt JA, Aune D, Byrnes G, Scalbert A, Agudo A, Rinaldi S. Coffee and tea drinking in relation to the risk of differentiated thyroid carcinoma: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Nutr 2019; 58:3303-3312. [PMID: 30535794 PMCID: PMC6850907 DOI: 10.1007/s00394-018-1874-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 12/01/2018] [Indexed: 01/12/2023]
Abstract
PURPOSE Coffee and tea constituents have shown several anti-carcinogenic activities in cellular and animal studies, including against thyroid cancer (TC). However, epidemiological evidence is still limited and inconsistent. Therefore, we aimed to investigate this association in a large prospective study. METHODS The study was conducted in the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort, which included 476,108 adult men and women. Coffee and tea intakes were assessed through validated country-specific dietary questionnaires. RESULTS During a mean follow-up of 14 years, 748 first incident differentiated TC cases (including 601 papillary and 109 follicular TC) were identified. Coffee consumption (per 100 mL/day) was not associated either with total differentiated TC risk (HRcalibrated 1.00, 95% CI 0.97-1.04) or with the risk of TC subtypes. Tea consumption (per 100 mL/day) was not associated with the risk of total differentiated TC (HRcalibrated 0.98, 95% CI 0.95-1.02) and papillary tumor (HRcalibrated 0.99, 95% CI 0.95-1.03), whereas an inverse association was found with follicular tumor risk (HRcalibrated 0.90, 95% CI 0.81-0.99), but this association was based on a sub-analysis with a small number of cancer cases. CONCLUSIONS In this large prospective study, coffee and tea consumptions were not associated with TC risk.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Via 199-203, 08908, L'Hospitalet de Llobregat, Spain.
| | - Muath A Alghamdi
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Via 199-203, 08908, L'Hospitalet de Llobregat, Spain
- College of Medicine, Al Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia
| | - Valerie Cayssials
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Via 199-203, 08908, L'Hospitalet de Llobregat, Spain
| | | | - Martin Almquist
- Department of Surgery, Skåne University Hospital Malmö, Lund University, Lund, Sweden
- Malmö Diet and Cancer Study, University Hospital Malmö, Malmö, Sweden
| | - Joakim Hennings
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - Maria Sandström
- Department for Radiation Sciences, Umeå University, Umeå, Sweden
| | - Konstantinos K Tsilidis
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
- School of Public Health, Imperial College London, London, UK
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Tromsø, Tromsö, Norway
- Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
| | - Marie-Christine Boutron-Ruault
- CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Bodil Hammer Bech
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Kim Overvad
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Anne Tjønneland
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kristina E N Petersen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Francesca Romana Mancini
- CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Yahya Mahamat-Saleh
- CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Fabrice Bonnet
- CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
- CHU Rennes, Université de Rennes 1, Rennes, France
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Renée T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece
- Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, WHO Collaborating Center for Nutrition and Health, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Christina Bamia
- Hellenic Health Foundation, Athens, Greece
- Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, WHO Collaborating Center for Nutrition and Health, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Giovanna Masala
- Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy
| | - Sara Grioni
- Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Salvatore Panico
- Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, "Civic M.P. Arezzo" Hospital, ASP Ragusa, Ragusa, Italy
| | - Francesca Fasanelli
- Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and University of Turin, Turin, Italy
| | - Guri Skeie
- Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Tromsø, Tromsö, Norway
| | - Tonje Braaten
- Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Tromsø, Tromsö, Norway
| | - Cristina Lasheras
- Department of Functional Biology, Faculty of Medicine, University of Oviedo, Asturias, Spain
| | - Elena Salamanca-Fernández
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Pilar Amiano
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain
| | - Maria-Dolores Chirlaque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain
- Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain
| | - Aurelio Barricarte
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Jonas Manjer
- Department of Surgery, Skåne University Hospital Malmö, Lund University, Lund, Sweden
| | - Peter Wallström
- Nutrition Epidemiology Research Group, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - H Bas Bueno-de-Mesquita
- School of Public Health, Imperial College London, London, UK
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands
- Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Kay-Thee Khaw
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Nicholas J Wareham
- MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | | | - Dagfinn Aune
- School of Public Health, Imperial College London, London, UK
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Via 199-203, 08908, L'Hospitalet de Llobregat, Spain
| | - Sabina Rinaldi
- International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
15
|
Honaryar MK, Lunn RM, Luce D, Ahrens W, 't Mannetje A, Hansen J, Bouaoun L, Loomis D, Byrnes G, Vilahur N, Stayner L, Guha N. Welding fumes and lung cancer: a meta-analysis of case-control and cohort studies. Occup Environ Med 2019; 76:422-431. [PMID: 30948521 DOI: 10.1136/oemed-2018-105447] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 12/14/2018] [Accepted: 02/13/2019] [Indexed: 12/29/2022]
Abstract
BACKGROUND An estimated 110 million workers are exposed to welding fumes worldwide. Welding fumes are classified by the International Agency for Research on Cancer as carcinogenic to humans (group 1), based on sufficient evidence of lung cancer from epidemiological studies. OBJECTIVE To conduct a meta-analysis of case-control and cohort studies on welding or exposure to welding fumes and risk of lung cancer, accounting for confounding by exposure to asbestos and tobacco smoking. METHODS The literature was searched comprehensively in PubMed, reference lists of relevant publications and additional databases. Overlapping populations were removed. Meta-relative risks (mRRs) were calculated using random effects models. Publication bias was assessed using funnel plot, Eggers's test and Begg's test. RESULTS Forty-five studies met the inclusion criteria (20 case-control, 25 cohort/nested case-control), which reduced to 37 when overlapping study populations were removed. For 'ever' compared with 'never' being a welder or exposed to welding fumes, mRRs and 95% CIs were 1.29 (1.20 to 1.39; I2=26.4%; 22 studies) for cohort studies, 1.87 (1.53 to 2.29; I2=44.1%; 15 studies) for case-control studies and 1.17 (1.04 to 1.38; I2=41.2%) for 8 case-control studies that adjusted for smoking and asbestos exposure. The mRRs were 1.32 (95% CI 1.20 to 1.45; I2=6.3%; 15 studies) among 'shipyard welders', 1.44 (95% CI 1.07 to 1.95; I2=35.8%; 3 studies) for 'mild steel welders' and 1.38 (95% CI 0.89 to 2.13; I2=68.1%; 5 studies) among 'stainless steel welders'. Increased risks persisted regardless of time period, geographic location, study design, occupational setting, exposure assessment method and histological subtype. CONCLUSIONS These results support the conclusion that exposure to welding fumes increases the risk of lung cancer, regardless of the type of steel welded, the welding method (arc vs gas welding) and independent of exposure to asbestos or tobacco smoking.
Collapse
Affiliation(s)
- Manoj Kumar Honaryar
- International Agency for Research on Cancer, Lyon, France
- Service de médcine et addictologie, Centre Hospitalier des Quatre Villes (CH4V), Saint-Cloud et Sèvres, France
- Ecole des hautes études en santé publique (EHESP), Paris, France
| | - Ruth M Lunn
- National Institute of Environmental Health Sciences, Durham, North Carolina, USA
| | - Danièle Luce
- Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Pointe-à-Pitre, France
| | - Wolfgang Ahrens
- Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
| | - Andrea 't Mannetje
- Centre for Public Health Research, Massey University, Wellington, New Zealand
| | - Johnni Hansen
- Danish Cancer Society Research Center, København, Denmark
| | | | - Dana Loomis
- International Agency for Research on Cancer, Lyon, France
- University of Nevada, Reno, Reno, Nevada, USA
| | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - Nadia Vilahur
- International Agency for Research on Cancer, Lyon, France
- European Commission, Italy
| | - Leslie Stayner
- Division of Epidemiology and Biostatistics, University of Illinois, School of Public Health, Chicago, Illinois, USA
| | - Neela Guha
- International Agency for Research on Cancer, Lyon, France
- Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, California, USA
| |
Collapse
|
16
|
Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, Zvereva M, Hosen MI, Meziani S, De Tilly B, Polo G, Lole O, Francois P, Delhomme TM, Carreira C, Monteiro-Reis S, Henrique R, Abedi-Ardekani B, Byrnes G, Foll M, Weiderpass E, McKay J, Jeronimo C, Scelo G, Le Calvez-Kelm F. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine 2019; 44:431-438. [PMID: 31122840 PMCID: PMC6603852 DOI: 10.1016/j.ebiom.2019.05.004] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 05/02/2019] [Accepted: 05/02/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Recurrent mutations in the promoter of the telomerase reverse transcriptase (TERT) gene (C228T and C250T) detected in tumours and cells shed into urine of urothelial cancer (UC) patients are putative biomarkers for UC detection and monitoring. However, the possibility of detecting these mutations in cell-free circulating DNA (cfDNA) in blood and urine, or DNA from urinary exfoliated cells (cellDNA) with a single-gene sensitive assay has never been tested in a case-control setting. METHODS We developed a single-plex assay (UroMuTERT) for the detection of low-abundance TERT promoter mutations. We tested 93 primary and recurrent UC cases and 94 controls recruited in France (blood, urine samples and tumours for the cases), and 50 primary UC cases and 50 controls recruited in Portugal (urinary exfoliated cell samples). We compared our assay with urine cytology. FINDINGS In the French series, C228T or C250T were detected in urinary cfDNA or cellDNA in 81 cases (87·1%; 95% CI 78·6-93·2), and five controls (Specificity 94·7%; 95%CI 88·0-98·3), with 98·6% (95% CI 92·5-99·96) concordance in matched tumours. Detection rate in plasma cfDNA among cases was 7·1%. The UroMuTERT sensitivity was (i) highest for urinary cfDNA and cellDNA combined, (ii) consistent across primary and recurrent cases, tumour stages and grades, (iii) higher for low-risk non-muscle invasive UC (86·1%) than urine cytology (23·0%) (P < 0·0001) and (iv) 93·9% when combined with cytology. In the Portuguese series - the sensitivity and specificity for detection of UC with urinary cellDNA was 68·0% (95% CI 53·3-80·5) and 98·0% (95% CI 89·3-100·0). INTERPRETATION TERT promoter mutations detected by the UroMuTERT assay in urinary DNA (cfDNA or cellDNA) show excellent sensitivity and specificity for the detection of UC, significantly outperforming that of urine cytology notably for detection of low-grade early stages UC. FUND: French Cancer League; French Foster Research in Molecular Biology and European Commission FP7 Marie Curie COFUND.
Collapse
Affiliation(s)
| | - Arnaud Manel
- Protestant Clinic of Lyon, Urology department, Lyon, France
| | - Emmanuel Vian
- Protestant Clinic of Lyon, Urology department, Lyon, France
| | - Geoffroy Durand
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Nathalie Forey
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | - Maria Zvereva
- International Agency for Research on Cancer (IARC), Lyon, France; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Md Ismail Hosen
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Sonia Meziani
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | - Gilles Polo
- Protestant Clinic of Lyon, Urology department, Lyon, France
| | - Olesia Lole
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Pauline Francois
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | | | - Sara Monteiro-Reis
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal
| | - Rui Henrique
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal; Portuguese Oncology Institute of Porto (IPOP), Department of Pathology, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | | | - Graham Byrnes
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Matthieu Foll
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | - James McKay
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Carmen Jeronimo
- Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal; Portuguese Oncology Institute of Porto (IPOP), Department of Pathology, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | - Ghislaine Scelo
- International Agency for Research on Cancer (IARC), Lyon, France
| | | |
Collapse
|
17
|
Olivier M, Bouaoun L, Villar S, Robitaille A, Cahais V, Heguy A, Byrnes G, Le Calvez-Kelm F, Torres-Mejía G, Alvarado-Cabrero I, Imani-Razavi FS, Inés Sánchez G, Jaramillo R, Porras C, Rodriguez AC, Garmendia ML, Soto JL, Romieu I, Porter P, Guenthoer J, Rinaldi S. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS One 2019; 14:e0210372. [PMID: 30653559 PMCID: PMC6336331 DOI: 10.1371/journal.pone.0210372] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Accepted: 12/20/2018] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND In Latin America (LA), there is a high incidence rate of breast cancer (BC) in premenopausal women, and the genomic features of these BC remain unknown. Here, we aim to characterize the molecular features of BC in young LA women within the framework of the PRECAMA study, a multicenter population-based case-control study of BC in premenopausal women. METHODS Pathological tumor tissues were collected from incident cases from four LA countries. Immunohistochemistry (IHC) was performed centrally for ER, PR, HER2, Ki67, EGFR, CK5/6, and p53 protein markers. Targeted deep sequencing was done on genomic DNA extracted from formalin-fixed, paraffin-embedded tumor tissues and their paired blood samples to screen for somatic mutations in eight genes frequently mutated in BC. A subset of samples was analyzed by exome sequencing to identify somatic mutational signatures. RESULTS The majority of cases were positive for ER or PR (168/233; 72%), and 21% were triple-negative (TN), mainly of basal type. Most tumors were positive for Ki67 (189/233; 81%). In 126 sequenced cases, TP53 and PIK3CA were the most frequently mutated genes (32.5% and 21.4%, respectively), followed by AKT1 (9.5%). TP53 mutations were more frequent in HER2-enriched and TN IHC subtypes, whereas PIK3CA/AKT1 mutations were more frequent in ER-positive tumors, as expected. Interestingly, a higher proportion of G:C>T:A mutations was observed in TP53 in PRECAMA cases compared with TCGA and METABRIC BC series (27% vs 14%). Exome-wide mutational patterns in 10 TN cases revealed alterations in signal transduction pathways and major contributions of mutational signatures caused by altered DNA repair pathways. CONCLUSIONS These pilot results on PRECAMA tumors give a preview of the molecular features of premenopausal BC in LA. Although the overall mutation burden was as expected from data in other populations, mutational patterns observed in TP53 and exome-wide suggested possible differences in mutagenic processes giving rise to these tumors compared with other populations. Further -omics analyses of a larger number of cases in the near future will enable the investigation of relationships between these molecular features and risk factors.
Collapse
Affiliation(s)
- Magali Olivier
- Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, Lyon, France
| | - Liacine Bouaoun
- Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France
| | - Stephanie Villar
- Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, Lyon, France
| | - Alexis Robitaille
- Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, Lyon, France
| | - Vincent Cahais
- Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, Lyon, France
| | - Adriana Heguy
- Department of Pathology and Genome Technology Center, New York University Langone Medical Center, New York, United States of America
| | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France
| | - Florence Le Calvez-Kelm
- Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France
| | - Gabriela Torres-Mejía
- Center for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico
| | - Isabel Alvarado-Cabrero
- Department of Pathology, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Fazlollah Shahram Imani-Razavi
- Department of Pathology, UMAE Hospital de Gineco Obstetricia No. 4 "Luis Castelazo Ayala", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Gloria Inés Sánchez
- Group Infection and Cancer, School of Medicine, University of Antioquia, Medellín, Colombia
| | | | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas (ACIB)-Fundación INCIENSA, Costa Rica
| | - Ana Cecilia Rodriguez
- Agencia Costarricense de Investigaciones Biomédicas (ACIB)-Fundación INCIENSA, Costa Rica
| | | | | | - Isabelle Romieu
- Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France
| | - Peggy Porter
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States of America
| | - Jamie Guenthoer
- Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States of America
| | - Sabina Rinaldi
- Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
18
|
Olsson A, Bouaoun L, Auvinen A, Feychting M, Johansen C, Mathiesen T, Melin B, Lahkola A, Larjavaara S, Villegier AS, Byrnes G, Deltour I, Schüz J. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. J Neurooncol 2019; 141:139-149. [PMID: 30421160 DOI: 10.1007/s11060-018-03019-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 09/28/2018] [Indexed: 01/06/2023]
Abstract
PURPOSE Gliomas are the most common cancer of the brain, with a poor prognosis in particular for glioblastoma. In 2014, a study suggested reduced survival in relation to latency of mobile phone use among glioblastoma patients. A joint epidemiological/experimental project to study effects of RF-EMF on tumor development and progression was established. The current analysis relates to the epidemiological part and addresses whether pre-diagnostic mobile phone use was associated with survival among glioma patients. METHODS Glioma cases (n = 806) previously enrolled in a collaborative population-based case-control study in Denmark, Finland and Sweden were followed up for survival. Vital status, date of death, date of emigration, or date last known to be alive was obtained based on registry linkages with a unique personal ID in each country. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) stratified by country. Covariates investigated were sex, age, education, histology, treatment, anatomic location and marital status. RESULTS No indication of reduced survival among glioblastoma patients was observed for various measures of mobile phone use (ever regular use, time since start of regular use, cumulative call time overall or in the last 12 months) relative to no or non-regular use. All significant associations suggested better survival for mobile phone users. Results were similar for high-grade and low-grade gliomas. CONCLUSIONS We found no evidence of reduced survival among glioma patients in relation to previous mobile phone use.
Collapse
Affiliation(s)
- Ann Olsson
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France.
| | - Liacine Bouaoun
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Anssi Auvinen
- Faculty of Social Sciences, Health Sciences, University of Tampere, Tampere, Finland
| | - Maria Feychting
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Christoffer Johansen
- Oncology Clinic, 5073 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- Survivorship Unit, The Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Tiit Mathiesen
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
| | - Beatrice Melin
- Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden
| | - Anna Lahkola
- Radiation and Nuclear Safety Authority (STUK), Helsinki, Finland
| | | | | | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Isabelle Deltour
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Joachim Schüz
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon CEDEX 08, France
| |
Collapse
|
19
|
Guida F, Sun N, Bantis LE, Muller DC, Li P, Taguchi A, Dhillon D, Kundnani DL, Patel NJ, Yan Q, Byrnes G, Moons KGM, Tjønneland A, Panico S, Agnoli C, Vineis P, Palli D, Bueno-de-Mesquita B, Peeters PH, Agudo A, Huerta JM, Dorronsoro M, Barranco MR, Ardanaz E, Travis RC, Byrne KS, Boeing H, Steffen A, Kaaks R, Hüsing A, Trichopoulou A, Lagiou P, La Vecchia C, Severi G, Boutron-Ruault MC, Sandanger TM, Weiderpass E, Nøst TH, Tsilidis K, Riboli E, Grankvist K, Johansson M, Goodman GE, Feng Z, Brennan P, Johansson M, Hanash SM. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol 2018; 4:e182078. [PMID: 30003238 PMCID: PMC6233784 DOI: 10.1001/jamaoncol.2018.2078] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 04/10/2018] [Indexed: 11/14/2022]
Abstract
Importance There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Main Outcomes and Measures Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). Results In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. Conclusions and Relevance This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
Collapse
Affiliation(s)
- Florence Guida
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Nan Sun
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Leonidas E Bantis
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - David C Muller
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
| | - Peng Li
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Laboratory of Population Health, Max Planck Institute for Demographic Research, Rostock, Germany
| | - Ayumu Taguchi
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston
| | - Dilsher Dhillon
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Deepali L Kundnani
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Nikul J Patel
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Qingxiang Yan
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - Graham Byrnes
- Environment and Radiation Section, International Agency for Research on Cancer, Lyon, France
| | - Karel G M Moons
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands
| | - Anne Tjønneland
- Unit of Diet, Genes, and Environment, Danish Cancer Society Research Center, Copenhagen
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | - Claudia Agnoli
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Molecular and Genetic Epidemiology Unit, Human Genetics Foundation, Torino, Italy
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute-Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy
| | - Bas Bueno-de-Mesquita
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Department for Determinants of Chronic Diseases, National Institute for Public Health and the Environment, Bilthoven, Netherlands
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands
| | - Antonio Agudo
- Unit of Nutirition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jose M Huerta
- Department of Epidemiology, Murcia Regional Health Council, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Miren Dorronsoro
- Public Health Direction and Biodonostia Research Institute-CIBERESP, San Sebastian, Spain
| | - Miguel Rodriguez Barranco
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria, Granada, Spain
- Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - Eva Ardanaz
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Epidemiology, Prevention, and Promotion Health Service, Navarra Public Health Institute, Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Navarra Institute for Health Research, Pamplona, Spain
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Karl Smith Byrne
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke
| | - Annika Steffen
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke
| | - Rudolf Kaaks
- Divison of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg
| | - Anika Hüsing
- Divison of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece
- World Health Organization Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Pagona Lagiou
- Hellenic Health Foundation, Athens, Greece
- World Health Organization Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
| | - Carlo La Vecchia
- Hellenic Health Foundation, Athens, Greece
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy
| | - Gianluca Severi
- Molecular and Genetic Epidemiology Unit, Human Genetics Foundation, Torino, Italy
- Université Paris-Saclay, Université Paris-Sud, Université de Versailles Saint-Quentin-en-Yvelines, Centre de Recherche en Epidémiologie et Santé des Populations, National Institute for Health and Medical Research (INSERM), Villejuif, France
| | - Marie-Christine Boutron-Ruault
- Université Paris-Saclay, Université Paris-Sud, Université de Versailles Saint-Quentin-en-Yvelines, Centre de Recherche en Epidémiologie et Santé des Populations, National Institute for Health and Medical Research (INSERM), Villejuif, France
| | - Torkjel M Sandanger
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
| | - Elisabete Weiderpass
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
- Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
| | - Therese H Nøst
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
| | - Kostas Tsilidis
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
| | - Kjell Grankvist
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Gary E Goodman
- Public Health Sciences Division, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Ziding Feng
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Samir M Hanash
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| |
Collapse
|
20
|
Chanudet E, Wozniak MB, Bouaoun L, Byrnes G, Mukeriya A, Zaridze D, Brennan P, Muller DC, Scelo G. Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease. Int J Cancer 2017; 141:1730-1740. [PMID: 28639257 DOI: 10.1002/ijc.30845] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 05/31/2017] [Accepted: 06/06/2017] [Indexed: 12/31/2022]
Abstract
Circulating miRNAs have shown great promises as noninvasive diagnostic and predictive biomarkers in several solid tumors. While the miRNA profiles of renal tumors have been extensively explored, knowledge of their circulating counterparts is limited. Our study aimed to provide a large-scale genome-wide profiling of plasma circulating miRNA in clear-cell renal cell carcinoma (ccRCC). Plasma samples from 94 ccRCC cases and 100 controls were screened for 754 circulating micro-RNAs (miRNA) by TaqMan arrays. Analyses including known risk factors for renal cancer-namely, age, sex, hypertension, obesity, diabetes, tobacco smoking and alcohol consumption-highlighted that circulating miRNA profiles were tightly correlated with the stage of the disease. Advanced tumors, characterized as stage III and IV, were associated with specific miRNA signatures that significantly differ from both controls and earlier stage ccRCC cases. Molecular pathway enrichment analyses of their gene targets showed high similarities with alterations observed in renal tumors. Plasma circulating levels of miR-150 were significantly associated with RCC-specific survival and could marginally improve the predictive accuracy of clinical parameters in our series, including age at diagnosis, sex and conventional staging. In summary, our results suggest that circulating miRNAs may provide insights into renal cell carcinoma progression.
Collapse
Affiliation(s)
- Estelle Chanudet
- International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | | | - Liacine Bouaoun
- International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | - Graham Byrnes
- International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | - Anush Mukeriya
- Institute of Carcinogenesis, N. N. Blokhin Cancer Research Centre, Moscow, Russia
| | - David Zaridze
- Institute of Carcinogenesis, N. N. Blokhin Cancer Research Centre, Moscow, Russia
| | - Paul Brennan
- International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | | | - Ghislaine Scelo
- International Agency for Research on Cancer (WHO-IARC), Lyon, France
| |
Collapse
|
21
|
Hörnell A, Berg C, Forsum E, Larsson C, Sonestedt E, Åkesson A, Lachat C, Hawwash D, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Greenwood DC, Slimani N, Cevallos M, Egger M, Huybrechts I, Wirfält E. Perspective: An Extension of the STROBE Statement for Observational Studies in Nutritional Epidemiology (STROBE-nut): Explanation and Elaboration. Adv Nutr 2017; 8:652-678. [PMID: 28916567 PMCID: PMC5593101 DOI: 10.3945/an.117.015941] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 05/15/2017] [Accepted: 07/13/2017] [Indexed: 01/28/2023] Open
Abstract
Nutritional epidemiology is an inherently complex and multifaceted research area. Dietary intake is a complex exposure and is challenging to describe and assess, and links between diet, health, and disease are difficult to ascertain. Consequently, adequate reporting is necessary to facilitate comprehension, interpretation, and generalizability of results and conclusions. The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement is an international and collaborative initiative aiming to enhance the quality of reporting of observational studies. We previously presented a checklist of 24 reporting recommendations for the field of nutritional epidemiology, called "the STROBE-nut." The STROBE-nut is an extension of the general STROBE statement, intended to complement the STROBE recommendations to improve and standardize the reporting in nutritional epidemiology. The aim of the present article is to explain the rationale for, and elaborate on, the STROBE-nut recommendations to enhance the clarity and to facilitate the understanding of the guidelines. Examples from the published literature are used as illustrations, and references are provided for further reading.
Collapse
Affiliation(s)
- Agneta Hörnell
- Department of Food and Nutrition, Umeå University, Umeå, Sweden
| | - Christina Berg
- Department of Food and Nutrition, and Sport Science, University of Gothenburg, Gothenburg, Sweden
| | - Elisabet Forsum
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Christel Larsson
- Department of Food and Nutrition, and Sport Science, University of Gothenburg, Gothenburg, Sweden
| | - Emily Sonestedt
- Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
| | - Agneta Åkesson
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Carl Lachat
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Dana Hawwash
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Patrick Kolsteren
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - Willem De Keyzer
- Department of Biosciences and Food Sciences, University College Ghent, Ghent, Belgium
| | - John Van Camp
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Janet E Cade
- Nutritional Epidemiology Group, School of Food Science and Nutrition, and
| | - Darren C Greenwood
- Biostatistics Unit, School of Medicine, University of Leeds, Leeds, United Kingdom
| | - Nadia Slimani
- International Agency for Research on Cancer, Lyon, France
| | - Myriam Cevallos
- Department of Clinical Research, University of Bern, Bern, Switzerland
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
| | - Matthias Egger
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
| | | | - Elisabet Wirfält
- Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
| |
Collapse
|
22
|
Lonjou C, Damiola F, Moissonnier M, Durand G, Malakhova I, Masyakin V, Le Calvez-Kelm F, Cardis E, Byrnes G, Kesminiene A, Lesueur F. Investigation of DNA repair-related SNPs underlying susceptibility to papillary thyroid carcinoma reveals MGMT as a novel candidate gene in Belarusian children exposed to radiation. BMC Cancer 2017; 17:328. [PMID: 28499365 PMCID: PMC5429528 DOI: 10.1186/s12885-017-3314-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 05/02/2017] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Genetic factors may influence an individual's sensitivity to ionising radiation and therefore modify his/her risk of developing papillary thyroid carcinoma (PTC). Previously, we reported that common single nucleotide polymorphisms (SNPs) within the DNA damage recognition gene ATM contribute to PTC risk in Belarusian children exposed to fallout from the Chernobyl power plant accident. Here we explored in the same population the contribution of a panel of DNA repair-related SNPs in genes acting downstream of ATM. METHODS The association of 141 SNPs located in 43 DNA repair genes was examined in 75 PTC cases and 254 controls from the Gomel region in Belarus. All subjects were younger than 15 years at the time of the Chernobyl accident. Conditional logistic regressions accounting for radiation dose were performed with PLINK using the additive allelic inheritance model, and a linkage disequilibrium (LD)-based Bonferroni correction was used for correction for multiple testing. RESULTS The intronic SNP rs2296675 in MGMT was associated with an increased PTC risk [per minor allele odds ratio (OR) 2.54 95% CI 1.50, 4.30, P per allele = 0.0006, P corr.= 0.05], and gene-wide association testing highlighted a possible role for ERCC5 (P Gene = 0.01) and PCNA (P Gene = 0.05) in addition to MGMT (P Gene = 0.008). CONCLUSIONS These findings indicate that several genes acting in distinct DNA repair mechanisms contribute to PTC risk. Further investigation is needed to decipher the functional properties of the methyltransferase encoded by MGMT and to understand how alteration of such functions may lead to the development of the most common type of thyroid cancer.
Collapse
Affiliation(s)
- Christine Lonjou
- Institut Curie, 75248 Paris, France
- PSL Research University, 75005 Paris, France
- INSERM, U900, 75248 Paris, France
- Mines Paris Tech, 77305 Fontainebleau, France
| | | | - Monika Moissonnier
- Environment and Radiation, International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | | | - Irina Malakhova
- Republican Scientific and Practical Center for Medical Technologies, Informatisation, Administration and Management of Health (RSPC MT), 220013 Minsk, Belarus
| | - Vladimir Masyakin
- Republican Research Center for Radiation Medicine & Human Ecology, 246040 Gomel, Belarus
| | | | - Elisabeth Cardis
- Centre for Research in Environmental Epidemiology (CREAL), IMIM (Hospital del Mar Research Institute), CIBER Epidemiología y Salud Pública (CIBERESP), 08003 Barcelona, Spain
| | - Graham Byrnes
- Environment and Radiation, International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - Ausrele Kesminiene
- Environment and Radiation, International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - Fabienne Lesueur
- Institut Curie, 75248 Paris, France
- PSL Research University, 75005 Paris, France
- INSERM, U900, 75248 Paris, France
- Mines Paris Tech, 77305 Fontainebleau, France
| |
Collapse
|
23
|
Degli Esposti D, Sklias A, Lima SC, Beghelli-de la Forest Divonne S, Cahais V, Fernandez-Jimenez N, Cros MP, Ecsedi S, Cuenin C, Bouaoun L, Byrnes G, Accardi R, Sudaka A, Giordanengo V, Hernandez-Vargas H, Pinto LFR, Van Obberghen-Schilling E, Herceg Z. Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas. Genome Med 2017; 9:33. [PMID: 28381277 PMCID: PMC5382363 DOI: 10.1186/s13073-017-0419-z] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Accepted: 02/24/2017] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of cancers for which human papilloma virus (HPV) infection is an emerging risk factor. Previous studies showed promoter hypermethylation in HPV(+) oropharyngeal cancers, but only few consistent target genes have been so far described, and the evidence of a functional impact on gene expression is still limited. METHODS We performed global and stratified pooled analyses of epigenome-wide data in HNSCCs based on the Illumina HumanMethylation450 bead-array data in order to identify tissue-specific components and common viral epigenetic targets in HPV-associated tumours. RESULTS We identified novel differentially methylated CpGs and regions associated with viral infection that are independent of the anatomic site. In particular, most hypomethylated regions were characterized by a marked loss of CpG island boundaries, which showed significant correlations with expression of neighbouring genes. Moreover, a subset of only five CpGs in a few hypomethylated regions predicted HPV status with a high level of specificity in different cohorts. Finally, this signature was a better predictor of survival compared with HPV status determined by viral gene expression by RNA sequencing in The Cancer Genome Atlas cohort. CONCLUSIONS We identified a novel epigenetic signature of HPV infection in HNSCCs which is independent of the anatomic site, is functionally correlated with gene expression and may be leveraged for improved stratification of prognosis in HNSCCs.
Collapse
Affiliation(s)
- Davide Degli Esposti
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France.
| | - Athena Sklias
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Sheila C Lima
- Instituto Nacional de Cancer, Rio de Janeiro, Brazil
| | | | - Vincent Cahais
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Nora Fernandez-Jimenez
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Marie-Pierre Cros
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Szilvia Ecsedi
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
- MTA-DE Public Health Research Group, University of Debrecen, Debrecen, Hungary
| | - Cyrille Cuenin
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Liacine Bouaoun
- Environment Section, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Graham Byrnes
- Environment Section, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Rosita Accardi
- Infection Cancer Biology Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | - Anne Sudaka
- Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose (iBV), 06100, Nice, France
- Centre Antoine Lacassagne, Nice, 06189, France
| | - Valérie Giordanengo
- Université Côte d'Azur, Laboratoire de Virologie, CHU Nice-Archet, 06202, Nice, France
| | - Hector Hernandez-Vargas
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France
| | | | - Ellen Van Obberghen-Schilling
- Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose (iBV), 06100, Nice, France.
- Centre Antoine Lacassagne, Nice, 06189, France.
| | - Zdenko Herceg
- Epigenetics Group, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008, Lyon, France.
| |
Collapse
|
24
|
Ambatipudi S, Horvath S, Perrier F, Cuenin C, Hernandez-Vargas H, Le Calvez-Kelm F, Durand G, Byrnes G, Ferrari P, Bouaoun L, Sklias A, Chajes V, Overvad K, Severi G, Baglietto L, Clavel-Chapelon F, Kaaks R, Barrdahl M, Boeing H, Trichopoulou A, Lagiou P, Naska A, Masala G, Agnoli C, Polidoro S, Tumino R, Panico S, Dollé M, Peeters PHM, Onland-Moret NC, Sandanger TM, Nøst TH, Weiderpass E, Quirós JR, Agudo A, Rodriguez-Barranco M, Huerta Castaño JM, Barricarte A, Fernández AM, Travis RC, Vineis P, Muller DC, Riboli E, Gunter M, Romieu I, Herceg Z. DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. Eur J Cancer 2017; 75:299-307. [PMID: 28259012 PMCID: PMC5512160 DOI: 10.1016/j.ejca.2017.01.014] [Citation(s) in RCA: 90] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 12/16/2016] [Accepted: 01/20/2017] [Indexed: 01/12/2023]
Abstract
AIM OF THE STUDY A vast majority of human malignancies are associated with ageing, and age is a strong predictor of cancer risk. Recently, DNA methylation-based marker of ageing, known as 'epigenetic clock', has been linked with cancer risk factors. This study aimed to evaluate whether the epigenetic clock is associated with breast cancer risk susceptibility and to identify potential epigenetics-based biomarkers for risk stratification. METHODS Here, we profiled DNA methylation changes in a nested case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (n = 960) using the Illumina HumanMethylation 450K BeadChip arrays and used the Horvath age estimation method to calculate epigenetic age for these samples. Intrinsic epigenetic age acceleration (IEAA) was estimated as the residuals by regressing epigenetic age on chronological age. RESULTS We observed an association between IEAA and breast cancer risk (OR, 1.04; 95% CI, 1.007-1.076, P = 0.016). One unit increase in IEAA was associated with a 4% increased odds of developing breast cancer (OR, 1.04; 95% CI, 1.007-1.076). Stratified analysis based on menopausal status revealed that IEAA was associated with development of postmenopausal breast cancers (OR, 1.07; 95% CI, 1.020-1.11, P = 0.003). In addition, methylome-wide analyses revealed that a higher mean DNA methylation at cytosine-phosphate-guanine (CpG) islands was associated with increased risk of breast cancer development (OR per 1 SD = 1.20; 95 %CI: 1.03-1.40, P = 0.02) whereas mean methylation levels at non-island CpGs were indistinguishable between cancer cases and controls. CONCLUSION Epigenetic age acceleration and CpG island methylation have a weak, but statistically significant, association with breast cancer susceptibility.
Collapse
Affiliation(s)
| | - Steve Horvath
- Human Genetics and Biostatistics, University of California Los Angeles, Los Angeles, CA 90095-7088, USA
| | - Flavie Perrier
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Cyrille Cuenin
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | | | - Geoffroy Durand
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Pietro Ferrari
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Liacine Bouaoun
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Athena Sklias
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Véronique Chajes
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Kim Overvad
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Gianluca Severi
- Inserm, Centre de Recherche en Epidémiologie et Santé des Populations (CESP, U1018), Université Paris-Saclay, Université Paris-Sud, UVSQ, Institut Gustave Roussy, Villejuif, France; Human Genetics Foundation (HuGeF), Torino, Italy; Cancer Epidemiology Centre, Cancer Council Victoria and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourn, Australia
| | - Laura Baglietto
- Inserm, Centre de Recherche en Epidémiologie et Santé des Populations (CESP, U1018), Université Paris-Saclay, Université Paris-Sud, UVSQ, Institut Gustave Roussy, Villejuif, France; Cancer Epidemiology Centre, Cancer Council Victoria and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourn, Australia
| | - Françoise Clavel-Chapelon
- Inserm, Centre de Recherche en Epidémiologie et Santé des Populations (CESP, U1018), Université Paris-Saclay, Université Paris-Sud, UVSQ, Institut Gustave Roussy, Villejuif, France
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Myrto Barrdahl
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
| | - Pagona Lagiou
- Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece; Department of Epidemiology, Harvard School of Public Health, Boston, USA
| | - Androniki Naska
- Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
| | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy
| | - Claudia Agnoli
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | | | - Rosario Tumino
- Cancer Registry and Histopathology Unit, "Civic M.P. Arezzo" Hospital, ASP Ragusa, Italy
| | - Salvatore Panico
- Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
| | - Martijn Dollé
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Petra H M Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; MRC-PHE Centre for Environment and Health, Dept of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK
| | - N Charlotte Onland-Moret
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Torkjel M Sandanger
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
| | - Therese H Nøst
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway; Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
| | | | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Miguel Rodriguez-Barranco
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibsn Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
| | - José María Huerta Castaño
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
| | - Aurelio Barricarte
- Navarra Public Health Institute, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA) Pamplona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
| | - Ander Matheu Fernández
- Cellular Oncology Group, Biodonostia Health Research Institute, Paseo Dr. Beguiristain s/n, San Sebastian, Spain; IKERBASQUE, Basque Foundation, Spain
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health University of Oxford, Oxford UK
| | - Paolo Vineis
- School of Public Health, Imperial College London, London, UK
| | - David C Muller
- School of Public Health, Imperial College London, London, UK
| | - Elio Riboli
- School of Public Health, Imperial College London, London, UK
| | - Marc Gunter
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Isabelle Romieu
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Zdenko Herceg
- International Agency for Research on Cancer (IARC), Lyon, France.
| |
Collapse
|
25
|
Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017; 12:724-733. [PMID: 28034829 DOI: 10.1016/j.jtho.2016.12.019] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 12/19/2016] [Accepted: 12/19/2016] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Malignant mesothelioma is a deadly disease that is strongly associated with asbestos exposure. Peritoneal mesotheliomas account for 10% of all the cases. BRCA1 associated protein 1 (BAP1) is a deubiquitinating hydrolase that plays a key role in various cellular processes. Germline and somatic inactivation of BRCA1 associated protein 1 gene (BAP1) is frequent in pleural mesothelioma; however, little is known about its status in peritoneal mesothelioma. METHODS Taking advantage of the extensive French National Network for the Diagnosis of Malignant Pleural Mesothelioma and Rare Peritoneal Tumors and the French National Network for the Treatment of Rare Peritoneal Surface Malignancies, we collected biological material and clinical and epidemiological data for 46 patients with peritoneal mesothelioma. The status of BAP1 was evaluated at the mutational and protein expression levels and combined with our previous data on copy number alterations assessed in the same samples. RESULTS We detected mutations in 32% of the malignant peritoneal mesotheliomas analyzed. In addition, we have previously reported that copy number losses occurred in 42% of the samples included in this series. Overall, 73% of the malignant peritoneal mesotheliomas analyzed carried at least one inactivated BAP1 allele, but only 57% had a complete loss of its protein nuclear expression. Better overall survival was observed for patients with BAP1 mutations (p = 0.04), protein expression loss (p = 0.016), or at least one of these alterations (p = 0.007) independently of tumor histological subtype, age, and sex. CONCLUSIONS As in pleural mesothelioma, inactivation of BAP1 is frequent in peritoneal mesotheliomas. We found that BAP1 protein nuclear expression is a good prognostic factor and a more reliable marker for the complete loss of BAP1 activity than mutation or copy number loss.
Collapse
Affiliation(s)
- Noémie Leblay
- International Agency for Research on Cancer, Lyon, France
| | - Frédéric Leprêtre
- Structural and Functional Genomics Core Facility, University of Lille, Lille, France
| | - Nolwenn Le Stang
- Department of Biopathology, Cancer Center Lyon Leon Berard, Lyon, France; National Cancer Institute, Research Unit 1086, Caen, France
| | | | - Laurent Villeneuve
- Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; University Hospital of Lyon, Lyon, France
| | - Sylvie Isaac
- Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; Department of Pathology, University Hospital of Lyon and Lyon1 University, Lyon, France
| | - Denis Maillet
- Department of Oncology, University Hospital of Lyon and Lyon1 University, Lyon, France
| | - Françoise Galateau-Sallé
- Department of Biopathology, Cancer Center Lyon Leon Berard, Lyon, France; National Cancer Institute, Research Unit 1086, Caen, France
| | - Céline Villenet
- Structural and Functional Genomics Core Facility, University of Lille, Lille, France
| | - Shéhérazade Sebda
- Structural and Functional Genomics Core Facility, University of Lille, Lille, France
| | - Alexandra Goracci
- Department of Radiology, University Hospital of Lyon and Lyon1 University, Lyon, France
| | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - James D McKay
- International Agency for Research on Cancer, Lyon, France
| | - Martin Figeac
- Structural and Functional Genomics Core Facility, University of Lille, Lille, France; Sequencing Platform, Research Cancer Institute, Lille, France
| | - Olivier Glehen
- Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; Department of Surgery, University Hospital of Lyon and Lyon1 University, Lyon, France
| | - François-Noël Gilly
- Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; Department of Surgery, University Hospital of Lyon and Lyon1 University, Lyon, France
| | - Matthieu Foll
- International Agency for Research on Cancer, Lyon, France
| | | | - Marie Brevet
- Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; Department of Pathology, University Hospital of Lyon and Lyon1 University, Lyon, France
| |
Collapse
|
26
|
Brenner DR, Fanidi A, Grankvist K, Muller DC, Brennan P, Manjer J, Byrnes G, Hodge A, Severi G, Giles GG, Johansson M, Johansson M. Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies. Am J Epidemiol 2017; 185:86-95. [PMID: 27998891 DOI: 10.1093/aje/kww159] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 07/19/2016] [Indexed: 12/22/2022] Open
Abstract
To further investigate the role of inflammation in lung carcinogenesis, we evaluated associations between proinflammatory cytokines and lung cancer risk. We conducted a case-control study nested within 3 prospective cohort studies-the Melbourne Collaborative Cohort Study (1990-1994), the Malmö Diet and Cancer Study (1991-1996), and the Northern Sweden Health and Disease Study (initiated in 1985)-involving 807 incident lung cancer cases and 807 smoking-matched controls. Conditional logistic regression models adjusting for serum cotinine concentrations were used to estimate odds ratios for lung cancer risk associated with concentrations of interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-12, interferon γ, tumor necrosis factor α, and granulocyte-macrophage colony-stimulating factor. We observed a higher lung cancer risk for participants with elevated concentrations of IL-6 and IL-8. These associations seemed to be stronger among former smokers (for fourth quartile vs. first quartile, odds ratio (OR) = 2.70, 95% confidence interval (CI): 1.55, 4.70) and current smokers (OR = 1.99, 95% CI: 1.15, 3.44) for IL-6 and among former smokers (OR = 2.83, 95% CI: 1.18, 6.75) and current smokers (OR = 1.30, 95% CI: 0.69, 2.44) for IL-8. No notable associations were observed among never smokers. Risk associations with IL-6 and IL-8 were observed for blood samples taken close to diagnosis (<5 years) as well as more than 15 years postdiagnosis.
Collapse
|
27
|
Burton A, Byrnes G, Stone J, Tamimi RM, Heine J, Vachon C, Ozmen V, Pereira A, Garmendia ML, Scott C, Hipwell JH, Dickens C, Schüz J, Aribal ME, Bertrand K, Kwong A, Giles GG, Hopper J, Pérez Gómez B, Pollán M, Teo SH, Mariapun S, Taib NAM, Lajous M, Lopez-Riduara R, Rice M, Romieu I, Flugelman AA, Ursin G, Qureshi S, Ma H, Lee E, Sirous R, Sirous M, Lee JW, Kim J, Salem D, Kamal R, Hartman M, Miao H, Chia KS, Nagata C, Vinayak S, Ndumia R, van Gils CH, Wanders JOP, Peplonska B, Bukowska A, Allen S, Vinnicombe S, Moss S, Chiarelli AM, Linton L, Maskarinec G, Yaffe MJ, Boyd NF, dos-Santos-Silva I, McCormack VA. Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems. Breast Cancer Res 2016; 18:130. [PMID: 27993168 PMCID: PMC5168805 DOI: 10.1186/s13058-016-0787-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Accepted: 11/23/2016] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Inter-women and intra-women comparisons of mammographic density (MD) are needed in research, clinical and screening applications; however, MD measurements are influenced by mammography modality (screen film/digital) and digital image format (raw/processed). We aimed to examine differences in MD assessed on these image types. METHODS We obtained 1294 pairs of images saved in both raw and processed formats from Hologic and General Electric (GE) direct digital systems and a Fuji computed radiography (CR) system, and 128 screen-film and processed CR-digital pairs from consecutive screening rounds. Four readers performed Cumulus-based MD measurements (n = 3441), with each image pair read by the same reader. Multi-level models of square-root percent MD were fitted, with a random intercept for woman, to estimate processed-raw MD differences. RESULTS Breast area did not differ in processed images compared with that in raw images, but the percent MD was higher, due to a larger dense area (median 28.5 and 25.4 cm2 respectively, mean √dense area difference 0.44 cm (95% CI: 0.36, 0.52)). This difference in √dense area was significant for direct digital systems (Hologic 0.50 cm (95% CI: 0.39, 0.61), GE 0.56 cm (95% CI: 0.42, 0.69)) but not for Fuji CR (0.06 cm (95% CI: -0.10, 0.23)). Additionally, within each system, reader-specific differences varied in magnitude and direction (p < 0.001). Conversion equations revealed differences converged to zero with increasing dense area. MD differences between screen-film and processed digital on the subsequent screening round were consistent with expected time-related MD declines. CONCLUSIONS MD was slightly higher when measured on processed than on raw direct digital mammograms. Comparisons of MD on these image formats should ideally control for this non-constant and reader-specific difference.
Collapse
Affiliation(s)
- Anya Burton
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 09, France
| | - Graham Byrnes
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 09, France
| | - Jennifer Stone
- Centre for Genetic Origins of Health and Disease, Curtin University and the University of Western Australia, Perth, Australia
| | - Rulla M. Tamimi
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | | | - Celine Vachon
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA
| | - Vahit Ozmen
- Department of Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Ana Pereira
- Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile
| | | | - Christopher Scott
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA
| | - John H. Hipwell
- Centre for Medical Image Computing, University College London, London, UK
| | - Caroline Dickens
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Joachim Schüz
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 09, France
| | | | | | - Ava Kwong
- Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, People’s Republic of China
- Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong, People’s Republic of China
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria Australia
| | - John Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria Australia
| | - Beatriz Pérez Gómez
- Cancer Epidemiology Unit, Instituto de Salud Carlos III and CIBERESP, Madrid, Spain
| | - Marina Pollán
- Cancer Epidemiology Unit, Instituto de Salud Carlos III and CIBERESP, Madrid, Spain
| | - Soo-Hwang Teo
- Breast Cancer Research Group, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia
- Cancer Research Malaysia, Subang Jaya, Malaysia
| | | | - Nur Aishah Mohd Taib
- Breast Cancer Research Group, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia
| | - Martín Lajous
- Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA USA
- Center for Research on Population Health, Instituto Nacional de Salud Pública, Mexico City, Mexico
| | - Ruy Lopez-Riduara
- Center for Research on Population Health, Instituto Nacional de Salud Pública, Mexico City, Mexico
| | - Megan Rice
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Isabelle Romieu
- Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France
| | | | - Giske Ursin
- Cancer Registry of Norway, Oslo, Norway
- Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA USA
| | - Samera Qureshi
- Norwegian Center for Minority and Migrant Health Research (NAKMI), Oslo, Norway
| | - Huiyan Ma
- Department of Population Sciences, Beckman Research Institute, City of Hope, CA USA
| | - Eunjung Lee
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA USA
| | - Reza Sirous
- Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mehri Sirous
- Isfahan University of Medical Sciences, Isfahan, Iran
| | - Jong Won Lee
- Department of Surgery, Asan Medical Center, Seoul, Republic of Korea
| | - Jisun Kim
- Department of Surgery, Asan Medical Center, Seoul, Republic of Korea
| | | | - Rasha Kamal
- Woman Imaging Unit, Radiodiagnosis Department, Kasr El Aini, Cairo University Hospitals, Cairo, Egypt
| | - Mikael Hartman
- Department of Surgery, Yong Loo Lin School of Medicine, Singapore, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Hui Miao
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Kee-Seng Chia
- NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore, Singapore
| | | | | | - Rose Ndumia
- Aga Khan University Hospital, Nairobi, Kenya
| | - Carla H. van Gils
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Johanna O. P. Wanders
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | - Steve Allen
- Department of Imaging, Royal Marsden NHS Foundation Trust, London, UK
| | - Sarah Vinnicombe
- Division of Cancer Research, Ninewells Hospital & Medical School, Dundee, UK
| | - Sue Moss
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Anna M. Chiarelli
- Ontario Breast Screening Program, Cancer Care Ontario, Toronto, Canada
| | - Linda Linton
- Princess Margaret Cancer Centre, Toronto, Canada
| | | | | | | | - Isabel dos-Santos-Silva
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
| | - Valerie A. McCormack
- Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 09, France
| |
Collapse
|
28
|
Moskal A, Freisling H, Byrnes G, Assi N, Fahey MT, Jenab M, Ferrari P, Tjønneland A, Petersen KEN, Dahm CC, Hansen CP, Affret A, Boutron-Ruault MC, Cadeau C, Kühn T, Katzke V, Iqbal K, Boeing H, Trichopoulou A, Bamia C, Naska A, Masala G, de Magistris MS, Sieri S, Tumino R, Sacerdote C, Peeters PH, Bueno-de-Mesquita BH, Engeset D, Licaj I, Skeie G, Ardanaz E, Buckland G, Castaño JMH, Quirós JR, Amiano P, Molina-Portillo E, Winkvist A, Myte R, Ericson U, Sonestedt E, Perez-Cornago A, Wareham N, Khaw KT, Huybrechts I, Tsilidis KK, Ward H, Gunter MJ, Slimani N. Main nutrient patterns and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study. Br J Cancer 2016; 115:1430-1440. [PMID: 27764841 PMCID: PMC5129834 DOI: 10.1038/bjc.2016.334] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 09/16/2016] [Accepted: 09/25/2016] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Much of the current literature on diet-colorectal cancer (CRC) associations focused on studies of single foods/nutrients, whereas less is known about nutrient patterns. We investigated the association between major nutrient patterns and CRC risk in participants of the European Prospective Investigation into Cancer and Nutrition (EPIC) study. METHODS Among 477 312 participants, intakes of 23 nutrients were estimated from validated dietary questionnaires. Using results from a previous principal component (PC) analysis, four major nutrient patterns were identified. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed for the association of each of the four patterns and CRC incidence using multivariate Cox proportional hazards models with adjustment for established CRC risk factors. RESULTS During an average of 11 years of follow-up, 4517 incident cases of CRC were documented. A nutrient pattern characterised by high intakes of vitamins and minerals was inversely associated with CRC (HR per 1 s.d.=0.94, 95% CI: 0.92-0.98) as was a pattern characterised by total protein, riboflavin, phosphorus and calcium (HR (1 s.d.)=0.96, 95% CI: 0.93-0.99). The remaining two patterns were not significantly associated with CRC risk. CONCLUSIONS Analysing nutrient patterns may improve our understanding of how groups of nutrients relate to CRC.
Collapse
Affiliation(s)
- Aurélie Moskal
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Heinz Freisling
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Nada Assi
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Michael T Fahey
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Hawthorn, Melbourne, VIC 3122, Australia
| | - Mazda Jenab
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Pietro Ferrari
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Anne Tjønneland
- Danish Cancer Society Research Center, Unit of Diet, Genes and Environment, Strandboulevarden 49, Copenhagen DK-2100, Denmark
| | - Kristina EN Petersen
- Danish Cancer Society Research Center, Unit of Diet, Genes and Environment, Strandboulevarden 49, Copenhagen DK-2100, Denmark
| | - Christina C Dahm
- Section for Epidemiology, Department of Public Health, Aarhus University, Bartholins Alle 2, Aarhus C DK-8000, Denmark
| | - Camilla Plambeck Hansen
- Section for Epidemiology, Department of Public Health, Aarhus University, Bartholins Alle 2, Aarhus C DK-8000, Denmark
| | - Aurélie Affret
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM UMRS 1018, Villejuif F-94805, France
- Institut Gustave Roussy, Villejuif F-94805, France
| | - Marie-Christine Boutron-Ruault
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM UMRS 1018, Villejuif F-94805, France
- Institut Gustave Roussy, Villejuif F-94805, France
| | - Claire Cadeau
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM UMRS 1018, Villejuif F-94805, France
- Institut Gustave Roussy, Villejuif F-94805, France
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany
| | - Verena Katzke
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany
| | - Khalid Iqbal
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, Nuthetal 14558, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, Nuthetal 14558, Germany
| | - Antonia Trichopoulou
- Hellenic Health Foundation, 13 Kaisareias Street, Athens GR-115 27, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Mikras Asias 75, Goudi, Athens GR-115 27, Greece
| | - Christina Bamia
- Hellenic Health Foundation, 13 Kaisareias Street, Athens GR-115 27, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Mikras Asias 75, Goudi, Athens GR-115 27, Greece
| | - Androniki Naska
- Hellenic Health Foundation, 13 Kaisareias Street, Athens GR-115 27, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Mikras Asias 75, Goudi, Athens GR-115 27, Greece
| | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute–ISPO, Ponte Nuovo Palazzina 28A ‘Mario Fiori', Via delle Oblate 4, Florence 50141, Italy
| | - Maria Santucci de Magistris
- Department of Clinical and Experimental Medicine, Federico II University, via Pansini 5, 80131 Naples, Italy
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, Milano 20133, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, ‘Civic–M.P.Arezzo' Hospital, ASP, Via Dante No. 109, Ragusa 97100, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, University of Turin, Via Santena 7, Turin 10126, Italy
- Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Via Santena 7, Turin 10126, Italy
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Huispost Str. 6.131, PO Box 85500, Utrecht 3508 GA The Netherlands
- MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
| | - Bas H Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and The Environment (RIVM), PO Box 1, Bilthoven 3720 BA, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Heidelberglann 100, Utrecht 3584 CX, The Netherlands
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
- Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
| | - Dagrun Engeset
- The Norwegian Food Safety Authority, Head Office, Postboks 383, 2381 Brumunddal, Norway
| | - Idlir Licaj
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø N-9037, Norway
| | - Guri Skeie
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø N-9037, Norway
| | - Eva Ardanaz
- Navarra Public Health Institute, c/Leyre 15, Pamplona 31003, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Recinto de Complejo Hospitalario de Navarra c/Irunlarrea 3, Pamplona, 31008, Spain
- CIBER, Epidemiology and Public Health (CIBERESP), Melchor Fernández Almagro, 3-5, Madrid 28029, Spain
| | - Genevieve Buckland
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Avda Gran Via 199-203, 08908 Barcelona, Spain
| | - José M Huerta Castaño
- CIBER, Epidemiology and Public Health (CIBERESP), Melchor Fernández Almagro, 3-5, Madrid 28029, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Ronda de Levante 11, Murcia 30008, Spain
| | - José R Quirós
- Public Health Directorate, Asturias, Ciriaco Miguel Vigil St 9, Oviedo 33006, Spain
| | - Pilar Amiano
- CIBER, Epidemiology and Public Health (CIBERESP), Melchor Fernández Almagro, 3-5, Madrid 28029, Spain
- Public Health Division of Gipuzkoa-BIODonostia Research Institute, Basque Regional Health Department, 20013 San Sebastian, Spain
| | - Elena Molina-Portillo
- CIBER, Epidemiology and Public Health (CIBERESP), Melchor Fernández Almagro, 3-5, Madrid 28029, Spain
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, Hospitales Universitarios de Granada/Universidad de Granada, Cuesta del Observatorio, 4, Campus Universitario de Cartuja, Granada 18080, Spain
| | - Anna Winkvist
- Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, PO Box 459, 40530 Gothenburg, Sweden
- Department of Public Health and Clinical Medicine, Nutrition Research, Umeå University, SE-901 87 Umeå, Sweden
| | - Robin Myte
- Department of Radiation Sciences, Oncology, Umeå University, SE-901 87 Umeå, Sweden
| | - Ulrika Ericson
- Department of Clinical Sciences Malmö, Lund University, Box 117, SE-221 00 Lund, Sweden
| | - Emily Sonestedt
- Department of Clinical Sciences Malmö, Lund University, Box 117, SE-221 00 Lund, Sweden
| | - Aurora Perez-Cornago
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Oxford OX3 7LF, UK
| | - Nick Wareham
- MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Box 285, CB2 0QQ Cambridge, UK
| | - Kay-Tee Khaw
- Clinical Gerontology Unit, School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Rd, Cambridge CB2 0SP, UK
| | - Inge Huybrechts
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Konstantinos K Tsilidis
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, University Campus, Ionnina 45110, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, Cambridge
| | - Heather Ward
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, Cambridge
| | - Marc J Gunter
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Nadia Slimani
- International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| |
Collapse
|
29
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat 2016; 37:865-76. [PMID: 27328919 DOI: 10.1002/humu.23035] [Citation(s) in RCA: 513] [Impact Index Per Article: 64.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 06/18/2016] [Indexed: 12/12/2022]
Abstract
TP53 gene mutations are one of the most frequent somatic events in cancer. The IARC TP53 Database (http://p53.iarc.fr) is a popular resource that compiles occurrence and phenotype data on TP53 germline and somatic variations linked to human cancer. The deluge of data coming from cancer genomic studies generates new data on TP53 variations and attracts a growing number of database users for the interpretation of TP53 variants. Here, we present the current contents and functionalities of the IARC TP53 Database and perform a systematic analysis of TP53 somatic mutation data extracted from this database and from genomic data repositories. This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000). However, the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations, such as the presence of a significant number of mutations occurring outside the DNA-binding domain in specific cancer types. We also provide an update on TP53 inherited variants including the ones that should be considered as neutral frequent variations. We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database.
Collapse
Affiliation(s)
- Liacine Bouaoun
- Group of Biostatistics, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
| | - Dmitriy Sonkin
- Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Rockville, 9609, Maryland
| | - Maude Ardin
- Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
| | - Monica Hollstein
- Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
- Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK
| | - Graham Byrnes
- Group of Biostatistics, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
| | - Jiri Zavadil
- Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
| | - Magali Olivier
- Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
| |
Collapse
|
30
|
Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson CL, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology - nutritional epidemiology (STROBE-nut): An extension of the STROBE statement. NUTR BULL 2016; 41:240-251. [PMID: 27587981 PMCID: PMC4988500 DOI: 10.1111/nbu.12217] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Concerns have been raised about the quality of reporting in nutritional epidemiology. Research reporting guidelines such as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement can improve quality of reporting in observational studies. Herein, we propose recommendations for reporting nutritional epidemiology and dietary assessment research by extending the STROBE statement into Strengthening the Reporting of Observational Studies in Epidemiology - Nutritional Epidemiology (STROBE-nut). Recommendations for the reporting of nutritional epidemiology and dietary assessment research were developed following a systematic and consultative process, co-ordinated by a multidisciplinary group of 21 experts. Consensus on reporting guidelines was reached through a three-round Delphi consultation process with 53 external experts. In total, 24 recommendations for nutritional epidemiology were added to the STROBE checklist. When used appropriately, reporting guidelines for nutritional epidemiology can contribute to improve reporting of observational studies with a focus on diet and health.
Collapse
Affiliation(s)
- C Lachat
- Department of Food Safety and Food Quality Ghent University Ghent Belgium; Unit of Nutrition and Child Health Institute of Tropical Medicine Antwerp Belgium
| | - D Hawwash
- Department of Food Safety and Food Quality Ghent University Ghent Belgium
| | - M C Ocké
- National Institute for Public Health and the Environment Bilthoven The Netherlands
| | - C Berg
- Department of Food and Nutrition, and Sport Science University of Gothenburg Gothenburg Sweden
| | - E Forsum
- Department of Clinical and Experimental Medicine Linköping University Linköping Sweden
| | - A Hörnell
- Department of Food and Nutrition Umeå University Umeå Sweden
| | - C L Larsson
- Department of Food and Nutrition, and Sport Science University of Gothenburg Gothenburg Sweden
| | - E Sonestedt
- Department of Clinical Sciences Malmö Lund University Malmö Sweden
| | - E Wirfält
- Department of Clinical Sciences Malmö Lund University Malmö Sweden
| | - A Åkesson
- Institute of Environmental Medicine Karolinska Institutet Stockholm Sweden
| | - P Kolsteren
- Department of Food Safety and Food Quality Ghent University Ghent Belgium; Unit of Nutrition and Child Health Institute of Tropical Medicine Antwerp Belgium
| | - G Byrnes
- International Agency for Research on Cancer Lyon France
| | - W De Keyzer
- Department of Biosciences and Food Sciences University College Ghent Ghent Belgium
| | - J Van Camp
- Department of Food Safety and Food Quality Ghent University Ghent Belgium
| | - J E Cade
- School of Food Science and Nutrition University of Leeds Leeds UK
| | - N Slimani
- International Agency for Research on Cancer Lyon France
| | - M Cevallos
- Institute of Social and Preventive Medicine University of Bern Bern Switzerland; Department of Clinical Research University of Bern Bern Switzerland
| | - M Egger
- Institute of Social and Preventive Medicine University of Bern Bern Switzerland
| | - I Huybrechts
- International Agency for Research on Cancer Lyon France
| |
Collapse
|
31
|
Freisling H, Pisa PT, Ferrari P, Byrnes G, Moskal A, Dahm CC, Vergnaud AC, Boutron-Ruault MC, Fagherazzi G, Cadeau C, Kühn T, Neamat-Allah J, Buijsse B, Boeing H, Halkjær J, Tjonneland A, Hansen CP, Quirós JR, Travier N, Molina-Montes E, Amiano P, Huerta JM, Barricarte A, Khaw KT, Wareham N, Key TJ, Romaguera D, Lu Y, Lassale CM, Naska A, Orfanos P, Trichopoulou A, Masala G, Pala V, Berrino F, Tumino R, Ricceri F, de Magistris MS, Bueno-de-Mesquita HB, Ocké MC, Sonestedt E, Ericson U, Johansson M, Skeie G, Weiderpass E, Braaten T, Peeters PHM, Slimani N. Main nutrient patterns are associated with prospective weight change in adults from 10 European countries. Eur J Nutr 2016; 55:2093-104. [PMID: 26303194 DOI: 10.1007/s00394-015-1023-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Accepted: 08/13/2015] [Indexed: 01/10/2023]
Abstract
PURPOSE Various food patterns have been associated with weight change in adults, but it is unknown which combinations of nutrients may account for such observations. We investigated associations between main nutrient patterns and prospective weight change in adults. METHODS This study includes 235,880 participants, 25-70 years old, recruited between 1992 and 2000 in 10 European countries. Intakes of 23 nutrients were estimated from country-specific validated dietary questionnaires using the harmonized EPIC Nutrient DataBase. Four nutrient patterns, explaining 67 % of the total variance of nutrient intakes, were previously identified from principal component analysis. Body weight was measured at recruitment and self-reported 5 years later. The relationship between nutrient patterns and annual weight change was examined separately for men and women using linear mixed models with random effect according to center controlling for confounders. RESULTS Mean weight gain was 460 g/year (SD 950) and 420 g/year (SD 940) for men and women, respectively. The annual differences in weight gain per one SD increase in the pattern scores were as follows: principal component (PC) 1, characterized by nutrients from plant food sources, was inversely associated with weight gain in men (-22 g/year; 95 % CI -33 to -10) and women (-18 g/year; 95 % CI -26 to -11). In contrast, PC4, characterized by protein, vitamin B2, phosphorus, and calcium, was associated with a weight gain of +41 g/year (95 % CI +2 to +80) and +88 g/year (95 % CI +36 to +140) in men and women, respectively. Associations with PC2, a pattern driven by many micro-nutrients, and with PC3, a pattern driven by vitamin D, were less consistent and/or non-significant. CONCLUSIONS We identified two main nutrient patterns that are associated with moderate but significant long-term differences in weight gain in adults.
Collapse
Affiliation(s)
- Heinz Freisling
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France.
| | - Pedro T Pisa
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
- Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa
| | - Pietro Ferrari
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
| | - Aurelie Moskal
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
| | - Christina C Dahm
- Section of Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - Anne-Claire Vergnaud
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Marie-Christine Boutron-Ruault
- Centre for Research in Epidemiology and Population Health (CESP), Nutrition, Hormones and Women's Health Team, INSERM, Villejuif, France
- Université Paris Sud, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Guy Fagherazzi
- Centre for Research in Epidemiology and Population Health (CESP), Nutrition, Hormones and Women's Health Team, INSERM, Villejuif, France
- Université Paris Sud, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Claire Cadeau
- Centre for Research in Epidemiology and Population Health (CESP), Nutrition, Hormones and Women's Health Team, INSERM, Villejuif, France
- Université Paris Sud, Villejuif, France
- Institut Gustave Roussy, Villejuif, France
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jasmine Neamat-Allah
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Brian Buijsse
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
| | - Jytte Halkjær
- Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
| | - Anne Tjonneland
- Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
| | - Camilla P Hansen
- Section of Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | | | - Noémie Travier
- Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - Esther Molina-Montes
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, Hospitales Universitarios de Granada, Universidad de Granada, Granada, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Pilar Amiano
- Public Helath Division of Gipuzkoa, Basque Health Department, BioDonostia Research Institute, San Sebastián, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain
| | - José M Huerta
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
| | - Aurelio Barricarte
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain
- Navarre Public Health Institute, Pamplona, Spain
| | - Kay-Tee Khaw
- Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, UK
| | - Nicholas Wareham
- Medical Research Council Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Tim J Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Dora Romaguera
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
- Instituto de Investigación Sanitaria de Palma (IdISPa), CIBER Fisiopatología de la Obesidad y Nutrición (CIBER-OBN), Madrid, Spain
| | - Yunxia Lu
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Camille M Lassale
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Androniki Naska
- Hellenic Health Foundation, Athens, Greece
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
| | - Philippos Orfanos
- Hellenic Health Foundation, Athens, Greece
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
| | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence, Italy
| | - Valeria Pala
- Epidemiology and Prevention Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Franco Berrino
- Epidemiology and Prevention Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Rosario Tumino
- Cancer Registry, Azienda Ospedaliera "Civile M.P. Arezzo", Ragusa, Italy
| | - Fulvio Ricceri
- Unit of Cancer Epidemiology - CERMS, Department of Medical Sciences, University of Turin and Città della Salute e della Scienza Hospital, Turin, Italy
| | | | - H Bas Bueno-de-Mesquita
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands
- Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Marga C Ocké
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Emily Sonestedt
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Ulrika Ericson
- Diabetes and Cardiovascular Disease, Genetic Epidemiology, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Mattias Johansson
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
- Department of Biobank Research, Umea University, Umeå, Sweden
| | - Guri Skeie
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsö, Norway
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsö, Norway
- Cancer Registry of Norway, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland
| | - Tonje Braaten
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsö, Norway
| | - Petra H M Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Nadia Slimani
- International Agency for Research on Cancer (IARC-WHO), 150, Cours Albert Thomas, 69372, Lyon Cedex 08, France
| |
Collapse
|
32
|
Vinayanuwattikun C, Le Calvez-Kelm F, Abedi-Ardekani B, Zaridze D, Mukeria A, Voegele C, Vallée M, Purnomosari D, Forey N, Durand G, Byrnes G, Mckay J, Brennan P, Scelo G. Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. Sci Rep 2016; 6:31628. [PMID: 27545006 PMCID: PMC4992872 DOI: 10.1038/srep31628] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Accepted: 07/19/2016] [Indexed: 01/09/2023] Open
Abstract
To examine the diversity of somatic alterations and clonal evolution according to aggressiveness of disease, nineteen tumor-blood pairs of 'formerly bronchiolo-alveolar carcinoma (BAC)' which had been reclassified into preinvasive lesion (adenocarcinoma in situ; AIS), focal invasive lesion (minimally invasive adenocarcinoma; MIA), and invasive lesion (lepidic predominant adenocarcinoma; LPA and non-lepidic predominant adenocarcinoma; non-LPA) according to IASLC/ATS/ERS 2011 classification were explored by whole exome sequencing. Several distinct somatic alterations were observed compare to the lung adenocarcinoma study from the Cancer Genome Atlas (TCGA). There were higher numbers of tumors with significant APOBEC mutation fold enrichment (73% vs. 58% TCGA). The frequency of KRAS mutations was lower in our study (5% vs. 32% TCGA), while a higher number of mutations of RNA-splicing genes, RBM10 and U2AF1, were found (37% vs. 11% TCGA). We found neither mutational pattern nor somatic copy number alterations that were specific to AIS/MIA. We demonstrated that clonal cell fraction was the only distinctive feature that discriminated LPA/non-LPA from AIS/MIA. The broad range of clonal frequency signified a more branched clonal evolution at the time of diagnosis. Assessment of tumor clonal cell fraction might provide critical information for individualized therapy as a prognostic factor, however this needs further study.
Collapse
Affiliation(s)
- Chanida Vinayanuwattikun
- International Agency for Research on Cancer, Lyon, France
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | | | | | - David Zaridze
- Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation
| | - Anush Mukeria
- Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation
| | | | - Maxime Vallée
- International Agency for Research on Cancer, Lyon, France
- Department of Molecular Medicine, CHUQ Research Center, Laval University, Quebec, Canada
| | - Dewajani Purnomosari
- International Agency for Research on Cancer, Lyon, France
- Department of Histology and Cell Biology and Molecular Biology Laboratory, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
| | - Nathalie Forey
- International Agency for Research on Cancer, Lyon, France
| | | | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - James Mckay
- International Agency for Research on Cancer, Lyon, France
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, France
| | | |
Collapse
|
33
|
Fernandez-Cuesta L, Perdomo S, Avogbe PH, Leblay N, Delhomme TM, Gaborieau V, Abedi-Ardekani B, Chanudet E, Olivier M, Zaridze D, Mukeria A, Vilensky M, Holcatova I, Polesel J, Simonato L, Canova C, Lagiou P, Brambilla C, Brambilla E, Byrnes G, Scelo G, Le Calvez-Kelm F, Foll M, McKay JD, Brennan P. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine 2016; 10:117-23. [PMID: 27377626 PMCID: PMC5036515 DOI: 10.1016/j.ebiom.2016.06.032] [Citation(s) in RCA: 137] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 06/20/2016] [Accepted: 06/23/2016] [Indexed: 12/18/2022] Open
Abstract
Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis surveillance but it may also play a crucial role in the detection of pre-clinical cancer. Small-cell lung cancer (SCLC) is an excellent candidate for early detection given there are no successful therapeutic options for late-stage disease, and it displays almost universal inactivation of TP53. We assessed the presence of TP53 mutations in the cell-free DNA (cfDNA) extracted from the plasma of 51 SCLC cases and 123 non-cancer controls. We identified mutations using a pipeline specifically designed to accurately detect variants at very low fractions. We detected TP53 mutations in the cfDNA of 49% SCLC patients and 11.4% of non-cancer controls. When stratifying the 51 initial SCLC cases by stage, TP53 mutations were detected in the cfDNA of 35.7% early-stage and 54.1% late-stage SCLC patients. The results in the controls were further replicated in 10.8% of an independent series of 102 non-cancer controls. The detection of TP53 mutations in 11% of the 225 non-cancer controls suggests that somatic mutations in cfDNA among individuals without any cancer diagnosis is a common occurrence, and poses serious challenges for the development of ctDNA screening tests.
Collapse
Affiliation(s)
- Lynnette Fernandez-Cuesta
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Sandra Perdomo
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France; Institute of Nutrition, Genetics and Metabolism Research, Universidad El Bosque, Bogotá, Colombia
| | - Patrice H Avogbe
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Noemie Leblay
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Tiffany M Delhomme
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Valerie Gaborieau
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Behnoush Abedi-Ardekani
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Estelle Chanudet
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Magali Olivier
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - David Zaridze
- Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation
| | - Anush Mukeria
- Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation
| | | | - Ivana Holcatova
- 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | - Lorenzo Simonato
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Cristina Canova
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | | | | | | | - Graham Byrnes
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Ghislaine Scelo
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Florence Le Calvez-Kelm
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - Matthieu Foll
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France
| | - James D McKay
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France.
| | - Paul Brennan
- International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyons, France.
| |
Collapse
|
34
|
Avogbe PH, Delhomme T, Leblay N, Le Calvez-Kelm F, Chopard P, Gaborieau V, Scelo G, Abedi-Ardekani B, Zaridze D, Mukeria A, Byrnes G, Brennan P, Fernandez-Cuesta L, Foll M, McKay JD. Abstract 3156: NGS-based screening for TP53 mutations in circulating cell-free DNA: A first step towards early detection of lung cancers. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The US National Lung Cancer Screening Trial (NLST) demonstrated in 2011 that screening with computed tomography (CT) scans could reduce lung cancer mortality by 20%, but with important financial costs and high number of false positives. The identification of novel biomarkers is a need to obtain the maximum benefit from CT screening. Given its economical and minimally invasive nature, screening for somatic mutations in circulating tumor DNA (ctDNA) using next-generation sequencing may complement existing screening tools. However, for application in early detection, variant detection must also be done agnostically, i.e. without prior knowledge from tumour tissue of the mutations expected and unfortunately, most currently available variant callers are not adapted for this task.
Methods
We performed multiplex PCR on circulating free DNA (cfDNA) extracted from the plasma of 35 lung squamous cell carcinoma (SCC) and 64 small-cell carcinoma (SCLC) patients. We additionally included 133 hospital controls to evaluate the specificity of ctDNA. We applied (>10,000X) Ion torrent targeted sequencing on the full-coding region of TP53 since this gene is known to be mutated in more than 70% and 90% of SCC and SCLC, respectively. Each amplification, library preparation, and sequencing was performed in duplicate to control for amplification and sequencing errors. Detecting mutations on ctDNA raises important statistical and bioinformatics challenges as it represents only a small fraction of cfDNA. We therefore developed and applied a method based on the idea that a data-derived model of sequencing errors has the potential to improve our ability to detect low-allelic fraction (AF) somatic variants.
Results
We detected TP53 non-synonymous coding mutations with AFs between 0.04% and 85% (median 1.7%) in 8 (23%) SCC patients, 28 (44%) SCLC patients, and 8 (6%) controls. We estimated odds ratios of 4.6 (p = 0.006) for SCC and 12.0 (p = 6.7×10-10) for SCLC. Observations in controls are surprising, but in this instance there was no information regarding a subsequent cancer diagnosis.
Conclusion
We show that it is possible to detect ctDNA in the cfDNA of lung cancer patients. Since only patients with early stage (I-IIA) SCC tumours were included, these results support the potential utility of the approach for early detection. Nevertheless, if such mutations are found prior to diagnosis has not been explored in a prospective study design with pre-diagnostic plasma samples and individuals without a cancer diagnosis through a follow-up period.
Citation Format: Patrice H. Avogbe, Tiffany Delhomme, Noémie Leblay, Florence Le Calvez-Kelm, Priscilia Chopard, Valérie Gaborieau, Ghislaine Scelo, Behnoush Abedi-Ardekani, David Zaridze, Anush Mukeria, Graham Byrnes, Paul Brennan, Lynnette Fernandez-Cuesta, Matthieu Foll, James D. McKay. NGS-based screening for TP53 mutations in circulating cell-free DNA: A first step towards early detection of lung cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3156.
Collapse
Affiliation(s)
| | | | - Noémie Leblay
- 1International Agency for Research on Cancer, Lyon, France
| | | | | | | | | | | | - David Zaridze
- 2Russian N.N.Blokhin Cancer Research Centre, Moscow, Russian Federation
| | - Anush Mukeria
- 2Russian N.N.Blokhin Cancer Research Centre, Moscow, Russian Federation
| | - Graham Byrnes
- 1International Agency for Research on Cancer, Lyon, France
| | - Paul Brennan
- 1International Agency for Research on Cancer, Lyon, France
| | | | - Matthieu Foll
- 1International Agency for Research on Cancer, Lyon, France
| | - James D. McKay
- 1International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
35
|
Le Calvez-Kelm F, Foll M, Wozniak MB, Durand G, Chopard P, Pertesi M, Delhomme T, Holcatova I, Foretova L, Janout V, Fabianova E, Vallée MP, Brennan P, McKay JD, Byrnes G, Scélo G. Abstract 3137: NGS-based detection of KRAS hotspot mutations in plasma cell-free DNA of pancreatic cancer cases. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by hotspot mutations in the KRAS gene (codons 12, 13 or 61) in 85-90% of cases. Codon 12 KRAS mutations have been detected in pancreatic juice, blood and stool samples from pancreatic cancer cases and represent promising biomarkers for early detection. However, the proportion of tumor-derived KRAS mutations in cell-free DNA fragments (cfDNA) has shown large variations, probably because of the heterogeneity in biosamples and assays tested. Deep sequencing technologies (NGS) allow the identification of low-abundance somatic variants, but have not previously been applied to the detection of KRAS hotspot mutations in cfDNA of PDAC cases. Moreover, variant calling methods have rarely been tested against cancer-free individuals so the proportion of false positives is unknown. We investigated whether deep sequencing of KRAS mutations at codons 12, 13 and 61 in plasma samples could represent a robust assay to distinguish pancreatic cancer from chronic pancreatitis and healthy controls.
Methods: We developed an Ion Torrent-based NGS KRAS assay (partial exons 2 and 3, totalling 208bp) to screen cfDNA from plasma samples of 461 PDAC cases, 154 individuals with chronic pancreatitis and 421 healthy controls. cfDNA extraction (>4ng) and sequencing (>1000x coverage on average, and absence of systematic high sequencing error rates on the 208bp) performed well on 431 (93%) PDAC cases, 138 (90%) chronic pancreatitis, and 388 (95%) controls. We fit a robust negative-binomial regression to estimate the distribution of the sequencing errors at each DNA bp position and identified outlying samples, which were considered as KRAS positive when q-value<10-3. We also estimated the detection threshold of our assay using serial dilutions of DNA from SW480 KRAS mutated cell-line (p.G12V) in wild-type DNA.
Results: Sequencing of the serial dilutions of KRAS p.G12V mutated DNA indicated a detection threshold at a minor allele frequency of 0.2%. KRAS mutations in cfDNA were detected in 83 (19.3%) PDAC cases (73 on codon 12; 8 on codon 61; 1 on codon 13; and 1 multiple codons, i.e., similar in proportions as reported in tumor tissue from the International Cancer Genomic Consortium); 3 (2.2%) chronic pancreatitis (all on codon 12); and 8 (2.1%) healthy controls (4 on codon 12 and 4 on codon 61). Stage was significantly associated with the proportion of detected mutations in cancer cases (chi-squared p = 0.0005): the proportions of cases with detectable KRAS mutations in plasma were 7.9%, 14.9%, and 31.1% for local, regional, and advanced stages, respectively.
Conclusions: The NGS-based KRAS mutation screening is a sensitive approach to detect low allelic fraction in plasma cfDNA, although its utility for early detection is still limited. However, it has the capacity to identify specific KRAS mutations, which could be useful in a panel of other non-invasive biomarkers.
Citation Format: Florence Le Calvez-Kelm, Matthieu Foll, Magdalena B. Wozniak, Geoffroy Durand, Priscilia Chopard, Maroulio Pertesi, Tiffany Delhomme, Ivana Holcatova, Lenka Foretova, Vladimir Janout, Eleonora Fabianova, Maxime P. Vallée, Paul Brennan, James D. McKay, Graham Byrnes, Ghislaine Scélo. NGS-based detection of KRAS hotspot mutations in plasma cell-free DNA of pancreatic cancer cases. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3137.
Collapse
Affiliation(s)
| | - Matthieu Foll
- 1International Agency for Research on Cancer, LYON, France
| | | | | | | | | | | | - Ivana Holcatova
- 2Charles University of Prague, First Faculty of Medicine, Institute of Hygiene and Epidemiology, Prague, Czech Republic
| | - Lenka Foretova
- 3Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Brno, Czech Republic
| | - Vladimir Janout
- 4Department of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
| | - Eleonora Fabianova
- 5Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, Slovakia
| | | | - Paul Brennan
- 1International Agency for Research on Cancer, LYON, France
| | - James D. McKay
- 1International Agency for Research on Cancer, LYON, France
| | - Graham Byrnes
- 1International Agency for Research on Cancer, LYON, France
| | | |
Collapse
|
36
|
Olivier M, Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J. TP53 variations in human cancers: new lessons from the IARC TP53 Database and genomic studies. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61042-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, Wirfält E, Åkesson A, Kolsteren P, Byrnes G, De Keyzer W, Van Camp J, Cade JE, Slimani N, Cevallos M, Egger M, Huybrechts I. Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE Statement. PLoS Med 2016; 13:e1002036. [PMID: 27270749 PMCID: PMC4896435 DOI: 10.1371/journal.pmed.1002036] [Citation(s) in RCA: 260] [Impact Index Per Article: 32.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Concerns have been raised about the quality of reporting in nutritional epidemiology. Research reporting guidelines such as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement can improve quality of reporting in observational studies. Herein, we propose recommendations for reporting nutritional epidemiology and dietary assessment research by extending the STROBE statement into Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut). METHODS AND FINDINGS Recommendations for the reporting of nutritional epidemiology and dietary assessment research were developed following a systematic and consultative process, coordinated by a multidisciplinary group of 21 experts. Consensus on reporting guidelines was reached through a three-round Delphi consultation process with 53 external experts. In total, 24 recommendations for nutritional epidemiology were added to the STROBE checklist. CONCLUSION When used appropriately, reporting guidelines for nutritional epidemiology can contribute to improve reporting of observational studies with a focus on diet and health.
Collapse
Affiliation(s)
- Carl Lachat
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
- Unit of Nutrition and Child Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Dana Hawwash
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Marga C. Ocké
- National Institute for Public Health and the Environment, Bilthoven, the Netherlands
| | - Christina Berg
- Department of Food and Nutrition, and Sport Science, University of Gothenburg, Gothenburg, Sweden
| | - Elisabet Forsum
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Agneta Hörnell
- Department of Food and Nutrition, Umeå University, Umeå, Sweden
| | - Christel Larsson
- Department of Food and Nutrition, and Sport Science, University of Gothenburg, Gothenburg, Sweden
| | - Emily Sonestedt
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Elisabet Wirfält
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Agneta Åkesson
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Patrick Kolsteren
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
- Unit of Nutrition and Child Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Graham Byrnes
- International Agency for Research on Cancer, Lyon, France
| | - Willem De Keyzer
- Department of Biosciences and Food Sciences, University College Ghent, Ghent, Belgium
| | - John Van Camp
- Department of Food Safety and Food Quality, Ghent University, Ghent, Belgium
| | - Janet E. Cade
- Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, United Kingdom
| | - Nadia Slimani
- International Agency for Research on Cancer, Lyon, France
| | - Myriam Cevallos
- Department of Clinical Research, University of Bern, Bern, Switzerland
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
| | - Matthias Egger
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
| | | |
Collapse
|
38
|
Ardin M, Cahais V, Castells X, Bouaoun L, Byrnes G, Herceg Z, Zavadil J, Olivier M. MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes. BMC Bioinformatics 2016; 17:170. [PMID: 27091472 PMCID: PMC4835840 DOI: 10.1186/s12859-016-1011-z] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 04/04/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The nature of somatic mutations observed in human tumors at single gene or genome-wide levels can reveal information on past carcinogenic exposures and mutational processes contributing to tumor development. While large amounts of sequencing data are being generated, the associated analysis and interpretation of mutation patterns that may reveal clues about the natural history of cancer present complex and challenging tasks that require advanced bioinformatics skills. To make such analyses accessible to a wider community of researchers with no programming expertise, we have developed within the web-based user-friendly platform Galaxy a first-of-its-kind package called MutSpec. RESULTS MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources. MutSpec offers an accessible framework for building reproducible analysis pipelines, integrating existing methods and scripts developed in-house with publicly available R packages. MutSpec may be used to analyse data from whole-exome, whole-genome or targeted sequencing experiments performed on human or mouse genomes. Results are provided in various formats including rich graphical outputs. An example is presented to illustrate the package functionalities, the straightforward workflow analysis and the richness of the statistics and publication-grade graphics produced by the tool. CONCLUSIONS MutSpec offers an easy-to-use graphical interface embedded in the popular Galaxy platform that can be used by researchers with limited programming or bioinformatics expertise to analyse mutation signatures present in cancer genomes. MutSpec can thus effectively assist in the discovery of complex mutational processes resulting from exogenous and endogenous carcinogenic insults.
Collapse
Affiliation(s)
- Maude Ardin
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Vincent Cahais
- Epigenetic Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Xavier Castells
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Liacine Bouaoun
- Biostatistics Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Graham Byrnes
- Biostatistics Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Zdenko Herceg
- Epigenetic Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Jiri Zavadil
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, F69372, Lyon, France
| | - Magali Olivier
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, F69372, Lyon, France.
| |
Collapse
|
39
|
Tan IB, Chang ET, Chen CJ, Hsu WL, Chien YC, Hildesheim A, McKay JD, Gaborieau V, Kaderi MAB, Purnomosari D, Voegele C, LeCalvez-Kelm F, Byrnes G, Brennan P, Devi B, Li L, Zhang Y, Fan Y, Sun K, Du Z, Sun H, Chan AT, Tsao SW, Zeng YX, Tao Q, Busson P, Lhuillier C, Morales O, Mrizak D, Gelin A, Kapetanakis N, Delhem N, Mansouri S, Cao J, Vaidya A, Frappier L, Wai LK, Chen SH, Du JL, Ji MF, Huang QH, Liu Q, Cao SM, Doolan DL, Coghill A, Mulvenna J, Proietti C, Lekieffre L, Bethony J, Hildesheim AA, Fles R, Indrasari SR, Herdini C, Martini S, Isfandiari A, Rhomdoni A, Adham M, Mayangsari I, van Werkhoven E, Wildeman M, Hariwiyanto B, Hermani B, Kentjono WA, Haryana SM, Schmidt M, Tan IB, O’Sullivan B, Ozyar E, Lee AWM, Zeng MS, Gao X, Tang M, Martin P, Zeng Y, Carrington M, Coghill AE, Bu W, Nguyen H, Hsu WL, Yu KJ, Lou PJ, Wang CP, Chen CJ, Hildesheim A, Cohen JI, King AD, Chien YC, Hsu WL, Yu KJ, Chen TC, Lin CY, Tsou YA, Leu YS, Laio LJ, Chang YL, Wang CP, Hua CH, Wu MS, Hsiao CHK, Lee JC, Tsai MH, Cheng SHC, Lou PJ, Hildesheim A, Chen CJ, Hsu WL, Yu KJ, Chien YC, Chen TC, Lin CY, Tsou YA, Leu YS, Liao LJ, Chang YL, Yang TL, Hua CH, Wu MS, Hsiao CHK, Lee JC, Tsai MH, Cheng SHC, Ko JY, Hildesheim A, Chen CJ, Ko JMY, Dai W, Kwong D, Ng WT, Lee A, Ngan RKC, Yau CC, Tung S, Lung ML, Ji M, Sheng W, Ng MH, Cheng W, Yu X, Wu B, Wei K, Zhan J, Zeng YX, Cao SM, Xia N, Yuan Y, Cui Q, Xu M, Bei JX, Zeng YX, Şahin B, Dizman A, Esassolak M, İkizler AS, Yıldırım HC, Çaloğlu M, Atalar B, Akman F, Demiroz C, Atasoy BM, Canyilmaz E, Igdem S, Ugurluer G, Kütük T, Akmansoy M, Ozyar E, Sommat K, Wang FQ, Kwok LL, Tan T, Fong KW, Soong YL, Cheah SL, Wee J, Casanova M, Özyar E, Patte C, Orbach D, Ferrari A, Cristine VF, Errihani H, Pan J, Zhang L, Liji S, Grzegorzewski K, Gore L, Varan A, Hutajulu SH, Khuzairi G, Herdini C, Kusumo H, Hardianti MS, Taroeno-Hariadi KW, Purwanto I, Kurnianda J, Messick TE, Malecka K, Tolvinski L, Soldan S, Deakyne J, Song H, van den Heuvel A, Gu B, Cassel J, McDonnell M, Smith GR, Velvadapu V, Bian H, Zhang Y, Carlsen M, Chen S, Donald A, Lemmen C, Reitz AB, Lieberman PM, Chan KC, Chan LS, Lo KW, Yip TTC, Ngan RKC, Kahn M, Lung ML, Mak NK, Liu FF, Khaali W, Thariat J, Fantin L, Spirito F, Khyatti M, Driss EKB, Olivero S, Maryanski J, Doglio A, Xia M, Xia Y, Chang H, Shaw R, Rahaju P, Hardianti MS, Wisesa S, Taroeno-Harijadi KW, Purwanto I, Hariwiyanto B, Dhamiyati W, Kurnianda J, Tan SN, Sim SP, Yusuf M, Romdhoni AC, K WA, Rantam FA, Sugiyanto, Aryati L, Adi-Kusumo F, Hardianti MS, Bintoro SY, Oktriani R, Herawati C, Surono A, Haryana SM, Zhong L, Li L, Ma BB, Chan AT, Tao Q, Kalra M, Ngo M, Perna S, Leen A, Lapteva N, Rooney CM, Gottschalk S, Mustikaningtyas E, Herawati S, Romdhoni AC, Ji M, Xu Y, Cheng W, Ge S, Li F, Ng MH, Tan LSY, Wong B, Lim CM, Romdhoni AC, Rantam FA, Kentjono WA, Madani DZ, Akbar N, Permana AD, Herdini C, Indrasari SR, Fachiroh J, Hartati D, Rahayudjati TB, Darwis I, Hutajulu SH, Hariwiyanto B, Dhamiyati W, Purwanto I, Taroeno-Hariadi KW, Kurnianda J, Wisesa S, Hardianti MS, Hutajulu SH, Taroeno-Harijadi KW, Purwanto I, Herdini C, Dhamiyati W, Kurnianda J, Anwar K, Hutajulu SH, Indrasari SR, Dwidanarti SR, Purwanto I, Taroeno-Hariadi KW, Kurnianda J, Pramana DW, Hutajulu SH, Hariwiyanto B, Dhamiyati W, Purwanto I, Taroeno-Hariadi KW, Kurnianda J, Safitri DA, Hutajulu SH, Herdini C, Danarti SRD, Purwanto I, Taroeno-Hariadi KW, Kurnianda J, Taroeno SA, Wisesa S, Taroeno-Hariadi KW, Purwanto I, Hariwiyanto B, Dhamiyati W, Kurnianda J, Wijaya I, Oehadian A, Prasetya D, Hsu WL, Chien YC, Yu KJ, Wang CP, Lin CY, Tsou YA, Leu YS, Liao LJ, Chang YL, Ko JY, Hua CH, Wu MS, Hsiao CHK, Lee JC, Tsai MH, Cheng SHC, Lou PJ, Hildesheim A, Chen CJ, Rahman S, Budiman BJ, Novialdi, Rahmadona, Lestari DY, Yin C, Foussadier A, Blein E, Chen C, Ammour NB, Khiatti M, Cao S, Marzaini DSS, Hartati D, Rahayujati B, Herdini C, Fachiroh J, Gunawan L, Mubarika Haryana S, Surono A, Herawati C, Hartono M, Fachiroh J, Intansari U, Paramita DK, Akbar A, Fachiroh J, Paramita DK, Hermawan B, Rahayudjati TB, Paramita DK, Fachiroh J, Argy G, Fachiroh J, Paramita DK, Hutajulu SH, Sihotang TC, Fachiroh J, Intansari U, Paramita DK, Wahyono DJ, Soeharso P, Suryandari DA, Lisnawati, Musa Z, Hermani B, Daker M, Tzen YJ, Bakar N, Rahman ASAA, Ahmad M, Chia YT, Beng AKS, Sasikirana W, Wardana T, Radifar M, Herawati C, Surono A, Haryana SM. Proceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015. BMC Proc 2016. [PMCID: PMC4896251 DOI: 10.1186/s12919-016-0001-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
A1 Hope and despair in the current treatment of nasopharyngeal cancer IB Tan I1 NPC international incidence and risk factors Ellen T Chang I2 Familial nasopharyngeal carcinoma and the use of biomarkers Chien-Jen Chen, Wan-Lun Hsu, Yin-Chu Chien I3 Genetic susceptibility risk factors for sporadic and familial NPC: recent findings Allan Hildesheim I5 Genetic and environmental risk factors for nasopharyngeal cancer in Southeast Asia James D McKay, Valerie Gaborieau, Mohamed Arifin Bin Kaderi, Dewajani Purnomosari, Catherine Voegele, Florence LeCalvez-Kelm, Graham Byrnes, Paul Brennan, Beena Devi I6 Characterization of the NPC methylome identifies aberrant epigenetic disruption of key signaling pathways and EBV-induced gene methylation Li L, Zhang Y, Fan Y, Sun K, Du Z, Sun H, Chan AT, Tsao SW, Zeng YX, Tao Q I7 Tumor exosomes and translational research in NPC Pierre Busson, Claire Lhuillier, Olivier Morales, Dhafer Mrizak, Aurore Gelin, Nikiforos Kapetanakis, Nadira Delhem I8 Host manipulations of the Epstein-Barr virus EBNA1 protein Sheila Mansouri, Jennifer Cao, Anup Vaidya, and Lori Frappier I9 Somatic genetic changes in EBV-associated nasopharyngeal carcinoma Lo Kwok Wai I10 Preliminary screening results for nasopharyngeal carcinoma with ELISA-based EBV antibodies in Southern China Sui-Hong Chen, Jin-lin Du, Ming-Fang Ji, Qi-Hong Huang, Qing Liu, Su-Mei Cao I11 EBV array platform to screen for EBV antibodies associated with NPC and other EBV-associated disorders Denise L. Doolan, Anna Coghill, Jason Mulvenna, Carla Proietti, Lea Lekieffre, Jeffrey Bethony, and Allan Hildesheim I12 The nasopharyngeal carcinoma awareness program in Indonesia Renske Fles, Sagung Rai Indrasari, Camelia Herdini, Santi Martini, Atoillah Isfandiari, Achmad Rhomdoni, Marlinda Adham, Ika Mayangsari, Erik van Werkhoven, Maarten Wildeman, Bambang Hariwiyanto, Bambang Hermani, Widodo Ario Kentjono, Sofia Mubarika Haryana, Marjanka Schmidt, IB Tan I13 Current advances and future direction in nasopharyngeal cancer management Brian O’Sullivan I14 Management of juvenile nasopharyngeal cancer Enis Ozyar I15 Global pattern of nasopharyngeal cancer: correlation of outcome with access to radiotherapy Anne WM Lee I16 The predictive/prognostic biomarker for nasopharyngeal carcinoma Mu-Sheng Zeng I17 Effect of HLA and KIR polymorphism on NPC risk Xiaojiang Gao, Minzhong Tang, Pat Martin, Yi Zeng, Mary Carrington I18 Exploring the Association between Potentially Neutralizing Antibodies against EBV Infection and Nasopharyngeal Carcinoma Anna E Coghill, Wei Bu, Hanh Nguyen, Wan-Lun Hsu, Kelly J Yu, Pei-Jen Lou, Cheng-Ping Wang, Chien-Jen Chen, Allan Hildesheim, Jeffrey I Cohen I19 Advances in MR imaging in NPC Ann D King O1 Epstein-Barr virus seromarkers and risk of nasopharyngeal carcinoma: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan Yin-Chu Chien, Wan-Lun Hsu, Kelly J Yu, Tseng-Cheng Chen, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Laio, Yen-Liang Chang, Cheng-Ping Wang, Chun-Hun Hua, Ming-Shiang Wu, Chu-Hsing Kate Hsiao, Jehn-Chuan Lee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Pei-Jen Lou, Allan Hildesheim, Chien-Jen Chen O2 Familial tendency and environmental co-factors of nasopharyngeal carcinoma: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan Wan-Lun Hsu, Kelly J Yu, Yin-Chu Chien, Tseng-Cheng Chen, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Liao, Yen-Liang Chang, Tsung-Lin Yang, Chun-Hun Hua, Ming-ShiangWu, Chu-Hsing Kate Hsiao, Jehn-ChuanLee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Jenq-Yuh Ko, Allan Hildesheim, Chien-Jen Chen O3 The genetic susceptibility and prognostic role of TERT-CLPTM1L and genes in DNA damage pathways in NPC Josephine Mun Yee Ko, Wei Dai, Dora Kwong, Wai Tong Ng, Anne Lee, Roger Kai Cheong Ngan, Chun Chung Yau, Stewart Tung, Maria Li Lung O4 Long term effects of NPC screening Mingfang Ji, Wei Sheng, Mun Hon Ng, Weimin Cheng, Xia Yu, Biaohua Wu, Kuangrong Wei, Jun Zhan, Yi Xin Zeng, Su Mei Cao, Ningshao Xia, Yong Yuan O5 Risk prediction of nasopharyngeal carcinoma by detecting host genetic and Epstein-Barr virus variation in saliva Qian Cui, Miao Xu, Jin-Xin Bei, Yi-Xin Zeng O6 Patterns of care study in Turkish nasopharyngeal cancer patients (NAZOTURK): A Turkish Radiation Oncology Association Head and Neck Cancer Working Group Study B Şahin, A Dizman, M Esassolak, A Saran İkizler, HC Yıldırım, M Çaloğlu, B Atalar, F Akman, C Demiroz, BM Atasoy, E Canyilmaz, S Igdem, G Ugurluer, T Kütük, M Akmansoy, E Ozyar O7 Long term outcome of intensity modulated radiotherapy in nasopharyngeal carcinoma in National Cancer Centre Singapore Kiattisa Sommat, Fu Qiang Wang, Li-Lian Kwok, Terence Tan, Kam Weng Fong, Yoke Lim Soong, Shie Lee Cheah, Joseph Wee O8 International phase II randomized study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents M Casanova, E Özyar, C Patte, D Orbach, A Ferrari, VF Cristine, H Errihani, J Pan, L Zhang, S Liji, K Grzegorzewski, L Gore, A Varan O9 Prognostic impact of metastatic status in patients with nasopharyngeal carcinoma Susanna Hilda Hutajulu, Guntara Khuzairi, Camelia Herdini, Henry Kusumo, Mardiah Suci Hardianti, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Johan Kurnianda O10 Development of small molecule inhibitors of latent Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma Troy E. Messick, Kimberly Malecka, Lois Tolvinski, Samantha Soldan, Julianna Deakyne, Hui Song, Antonio van den Heuvel, Baiwei Gu, Joel Cassel, Mark McDonnell, Garry R Smith, Venkata Velvadapu, Haiyan Bian, Yan Zhang, Marianne Carlsen, Shuai Chen, Alastair Donald, Christian Lemmen, Allen B Reitz, Paul M Lieberman O11 Therapeutic targeting of cancer stem-like cells using a Wnt modulator, ICG-001, enhances the treatment outcome of EBV-positive nasopharyngeal carcinoma King Chi Chan, Lai Sheung Chan, Kwok Wai Lo, Timothy Tak Chun Yip, Roger Kai Cheong Ngan, Michael Kahn, Maria Li Lung, Nai Ki Mak O12 Role of micro-RNA in NPC biology Fei-Fei Liu O13 Expansion of EBNA1- and LMP2-specific effector T lymphocytes from patients with nasopharyngeal carcinoma without enhancement of regulatory T cells Wafa Khaali; Juliette Thariat; Laurence Fantin; Flavia Spirito; Meriem Khyatti; El Khalil Ben Driss; Sylvain Olivero; Janet Maryanski; Alain Doglio O14 The experience of patients’ life after amifostine radiotherapy treatment (ART) for nasopharyngeal carcinoma (NPC) Mengxue Xia, Yunfei Xia, Hui Chang, Rachel Shaw O15 Analysis of mitochondrial DNA mutation in latent membrane protein-1 positive nasopharyngeal carcinoma Pudji Rahaju O16 Factors influencing treatment adherence of nasopharyngeal cancer and the clinical outcomes: a hospital-based study Mardiah Suci Hardianti, Sindhu Wisesa, Kartika Widayati Taroeno-Harijadi, Ibnu Purwanto, Bambang Hariwiyanto, Wigati Dhamiyati, Johan Kurnianda O17 Chromosomal breaks mediated by bile acid-induced apoptosis in nasopharyngeal epithelial cells: in relation to matrix association region/scaffold attachment region Sang-Nee Tan, Sai-Peng Sim O18 Expression of p53 (wild type) on nasopharyngeal carcinoma stem cell that resistant to radiotherapy Muhtarum Yusuf, Ahmad C Romdhoni, Widodo Ario K, Fedik Abdul Rantam O19 Mathematical model of nasopharyngeal carcinoma in cellular level Sugiyanto, Lina Aryati, Fajar Adi-Kusumo, Mardiah Suci Hardianti O20 Differential expression of microRNA-21 on nasopharyngeal carcinoma plasma patient SY Bintoro, R Oktriani, C. Herawati, A Surono, Sofia M. Haryana O21 Therapeutic targeting of an oncogenic fibroblast growth factor-FGF19, which promotes proliferation and induces EMT of carcinoma cells through activating ERK and AKT signaling L. Zhong, L. Li, B. B. Ma, A. T. Chan, Q. Tao O22 Resist nasopharyngeal carcinoma (NPC): next generation T cells for the adoptive immunotherapy of NPC M. Kalra, M. Ngo, S. Perna, A. Leen, N. Lapteva, C. M. Rooney, S. Gottschalk O23 The correlation of heat shock protein 70 expressions and staging of nasopharyngeal carcinoma Elida Mustikaningtyas, Sri Herawati, Achmad C Romdhoni O24 Epstein-Barr virus serological profiles of nasopharyngeal carcinoma - A tribute to Werner Henle Mingfang Ji, YaruiXu, Weimin Cheng, ShengxiangGe, Fugui Li, M. H. Ng O25 Targeting the apoptosis pathway using combination TLR3 agonist with anti-survivin molecule (YM-155) in nasopharyngeal carcinoma Louise SY Tan, Benjamin Wong, CM Lim O26 The resistance mechanism of nasopharyngeal cancer stem cells to cisplatin through expression of CD44, Hsp70, p53 (wild type), Oct-4, and ß-catenin encoded-genes Achmad C Romdhoni, Fedik A. Rantam, Widodo Ario Kentjono P1 Prevalence of nasopharyngeal carcinoma patients at Departement of Otorhinolaringology-Head and Neck Surgery, Dr. Hasan Sadikin general hospital, Bandung, Indonesia in 2010-2014 Deasy Z Madani, Nur Akbar, Agung Dinasti Permana P2 Case report on pediatric nasopharyngeal carcinoma at Dr. Sardjito Hospital, Yogyakarta Camelia Herdini, Sagung Rai Indrasari, Jajah Fachiroh, Dwi Hartati, T. Baning Rahayudjati P3 Report on loco regionally advanced nasopharyngeal cancer patients treated with induction chemotherapy followed by concurrent chemo-radiation therapy Iswandi Darwis, Susanna Hilda Hutajulu, Bambang Hariwiyanto, Wigati Dhamiyati, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda P4 Sex and age differences in the survival of patients with nasopharyngeal carcinoma Sindhu Wisesa, Mardiah Suci Hardianti, Susanna Hilda Hutajulu, Kartika Widayati Taroeno-Harijadi, Ibnu Purwanto, Camelia Herdini, Wigati Dhamiyati, Johan Kurnianda P5 Impact of delayed diagnosis and delayed therapy in the treatment outcome of patients with nasopharyngeal carcinoma Khoirul Anwar, Susanna Hilda Hutajulu, Sagung Rai Indrasari, Sri Retna Dwidanarti, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda P6 Anaysis of pretreatment anemia in nasopharyngeal cancer patients undergoing neoadjuvant therapy Dominicus Wendhy Pramana, Susanna Hilda Hutajulu, Bambang Hariwiyanto, Wigati Dhamiyati, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda P7 Results of treatment with neoadjuvant cisplatin-5FU in locally advanced nasopharyngeal carcinoma: a local experience Diah Ari Safitri, Susanna Hilda Hutajulu, Camelia Herdini, Sri Retna Dwi Danarti, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda P8 Geriatrics with nasopharyngeal cancer Suryo A Taroeno, Sindhu Wisesa, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Bambang Hariwiyanto, Wigati Dhamiyati, Johan Kurnianda P9 Correlation of lymphocyte to monocyte and neutrophil to lymphocyte ratio to the response of cisplatin chemoradiotheraphy in locally advance nasopharyngeal carcinoma I. Wijaya, A. Oehadian, D. Prasetya P10 Prediction of nasopharyngeal carcinoma risk by Epstein-Barr virus seromarkers and environmental co-factors: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan Wan-Lun Hsu, Yin-Chu Chien, Kelly J Yu, Cheng-Ping Wang, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Liao, Yen-Liang Chang191,192, Jenq-Yuh Ko, Chun-Hun Hua, Ming-Shiang Wu, Chu-Hsing Kate Hsiao, Jehn-Chuan Lee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Pei-Jen Lou, Allan Hildesheim, Chien-Jen Chen P11 Non-viral risk factors for nasopharyngeal carcinoma in West Sumatra, Indonesia Sukri Rahman, Bestari J. Budiman, Novialdi, Rahmadona, Dewi Yuri Lestari P12 New prototype Vidas EBV IgA quick: performance on Chinese and Moroccan populations C. Yin, A. Foussadier, E. Blein, C. Chen, N. Bournet Ammour, M. Khiatti, S. Cao P13 The expression of EBV-LMP1 and VEGF as predictors and plasma EBV-DNA levels as early marker of distant metastasis after therapy in nasopharyngeal cancer Dewi Syafriyetti Soeis Marzaini P14 Characteristics and factors influencing subjects refusal for blood samples retrieval: lesson from NPC case control study in Yogyakarta – Indonesia Dwi Hartati, Baning Rahayujati, Camelia Herdini, Jajah Fachiroh P15 Expression of microRNA BART-7-3p and mRNA PTEN on blood plasma of patients with nasopharyngeal carcinoma L. Gunawan, S. Mubarika Haryana, A. Surono, C. Herawati P16 IgA response to native early antigen (IgA-EAext) of Epstein-Barr virus (EBV) in healthy population and nasopharyngeal carcinoma (NPC) patients: the potential for diagnosis and screening tools Michael Hartono, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita P17 IgA responses against Epstein-Barr Virus Early Antigen (EBV-EA) peptides as potential candidates of nasopharyngeal carcinoma detection marker Akmal Akbar, Jajah Fachiroh, Dewi Kartikawati Paramita P18 Association between smoking habit and IgA-EBV titer among healthy individuals in Yogyakarta, Indonesia Benny Hermawan, T Baning Rahayudjati, Dewi K Paramita, Jajah Fachiroh P19 Epstein-Barr virus IgA titer comparison of healthy non-family individuals and healthy first degree family of NPV patients Gabriella Argy, Jajah Fachiroh, Dewi Kartikawati Paramita, Susanna Hilda Hutajulu P20 Identification of EBV Early Antigen (EA) derived peptides for NPC diagnosis Theodora Caroline Sihotang, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita P21 Host-pathogen study: relative expression of mRNA BRLF1 Epstein-Barr virus as a potential biomarker for tumor progressivity and polymorphisms of TCRBC and TCRGC2 host genes related to genetic susceptibility on nasopharyngeal carcinoma Daniel Joko Wahyono, Purnomo Soeharso, Dwi Anita Suryandari, Lisnawati, Zanil Musa, Bambang Hermani P22 In vitro efficacy of silvestrol and episilvestrol, isolated from Borneo, on nasopharyngeal carcinoma, a major cancer in Borneo Maelinda Daker, Yeo Jiun Tzen, Norhasimah Bakar, Asma’ Saiyidatina Aishah Abdul Rahman, Munirah Ahmad, Yeo Tiong Chia, Alan Khoo Soo Beng P23 The expression of mir-141 in patients with nasopharyngeal cancer Widyandani Sasikirana, Tirta Wardana, Muhammad Radifar, Cita Herawati, Agus Surono, Sofia Mubarika Haryana
Collapse
|
40
|
Zamora-Ros R, Rinaldi S, Tsilidis KK, Weiderpass E, Boutron-Ruault MC, Rostgaard-Hansen AL, Tjønneland A, Clavel-Chapelon F, Mesrine S, Katzke VA, Kühn T, Förster J, Boeing H, Trichopoulou A, Lagiou P, Klinaki E, Masala G, Sieri S, Ricceri F, Tumino R, Mattiello A, Peeters PH, Bueno-de-Mesquita HB, Engeset D, Skeie G, Argüelles M, Agudo A, Sánchez MJ, Chirlaque MD, Barricarte A, Chamosa S, Almquist M, Tosovic A, Hennings J, Sandström M, Schmidt JA, Khaw KT, Wareham NJ, Cross AJ, Slimani N, Byrnes G, Romieu I, Riboli E, Franceschi S. Energy and macronutrient intake and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition study. Int J Cancer 2016; 138:65-73. [PMID: 26190646 PMCID: PMC6300115 DOI: 10.1002/ijc.29693] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 06/05/2015] [Accepted: 06/25/2015] [Indexed: 12/25/2022]
Abstract
Incidence rates of differentiated thyroid carcinoma (TC) have increased in many countries. Adiposity and dietary risk factors may play a role, but little is known on the influence of energy intake and macronutrient composition. The aim of this study was to investigate the associations between TC and the intake of energy, macronutrients, glycemic index (GI) and glycemic load in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The study included 477,274 middle-age participants (70.2% women) from ten European countries. Dietary data were collected using country-specific validated dietary questionnaires. Total carbohydrates, proteins, fats, saturated, monounsaturated and polyunsaturated fats (PUFA), starch, sugar, and fiber were computed as g/1,000 kcal. Multivariable Cox regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence interval (CI) by intake quartile (Q). After a mean follow-up time of 11 years, differentiated TC was diagnosed in 556 participants (90% women). Overall, we found significant associations only with total energy (HRQ4 vs .Q1 , 1.29; 95% CI, 1.00-1.68) and PUFA intakes (HRQ4 vs .Q1 , 0.74; 95% CI, 0.57-0.95). However, the associations with starch and sugar intake and GI were significantly heterogeneous across body mass index (BMI) groups, i.e., positive associations with starch and GI were found in participants with a BMI ≥ 25 and with sugar intake in those with BMI < 25. Moreover, inverse associations with starch and GI were observed in subjects with BMI < 25. In conclusion, our results suggest that high total energy and low PUFA intakes may increase the risk of differentiated TC. Positive associations with starch intake and GI in participants with BMI ≥ 25 suggest that those persons may have a greater insulin response to high starch intake and GI than lean people.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Sabina Rinaldi
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Konstantinos K. Tsilidis
- Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
- School of Public Health, Imperial College London, London, United Kingdom
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
- Department of Etiological Cancer Research, Cancer Registry of Norway, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland
| | - Marie-Christine Boutron-Ruault
- Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women’s Health team, F-94805, Villejuif, France
- Université Paris Sud, UMRS 1018, F-94805, Villejuif, France
- Institut Gustave Roussy, F-94805, Villejuif, France
| | | | | | - Françoise Clavel-Chapelon
- Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women’s Health team, F-94805, Villejuif, France
- Université Paris Sud, UMRS 1018, F-94805, Villejuif, France
- Institut Gustave Roussy, F-94805, Villejuif, France
| | - Sylvie Mesrine
- Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women’s Health team, F-94805, Villejuif, France
- Université Paris Sud, UMRS 1018, F-94805, Villejuif, France
- Institut Gustave Roussy, F-94805, Villejuif, France
| | - Verena A. Katzke
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jana Förster
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
- Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
- Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, US
| | | | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Fulvio Ricceri
- Unit of Cancer Epidemiology - CERMS, Department of Medical Sciences, University of Turin and Città della Salute e della Scienza Hospital, Turin, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, “Civic M.P. Arezzo” Hospital, ASP Ragusa, Italy
| | - Amalia Mattiello
- Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
| | - Petra H.M. Peeters
- School of Public Health, Imperial College London, London, United Kingdom
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - H. Bas Bueno-de-Mesquita
- School of Public Health, Imperial College London, London, United Kingdom
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Dagrun Engeset
- The Norwegian Scientific Committee for Food Safety (VKM), Oslo, Norway
| | - Guri Skeie
- Department of Community Medicine, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway
| | | | - Antonio Agudo
- Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain
| | - María-José Sánchez
- Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - María-Dolores Chirlaque
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain
| | - Aurelio Barricarte
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Institute of Navarra, Pamplona, Spain
| | - Saioa Chamosa
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, Health Department of Basque Region, San Sebastian
| | - Martin Almquist
- Department of Surgery, University Hospital Lund, Lund, Sweden
| | - Ada Tosovic
- Department of Surgery, University Hospital Malmö, Malmö, Sweden
| | - Joakim Hennings
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - Maria Sandström
- Department of Radiation Sciences, Oncology Umeå University, Umeå, Sweden
| | - Julie A Schmidt
- Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom
| | - Kay-Thee Khaw
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | | | - Amanda J. Cross
- School of Public Health, Imperial College London, London, United Kingdom
| | - Nadia Slimani
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Isabelle Romieu
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Elio Riboli
- School of Public Health, Imperial College London, London, United Kingdom
| | | |
Collapse
|
41
|
Assi N, Fages A, Vineis P, Chadeau-Hyam M, Stepien M, Duarte-Salles T, Byrnes G, Boumaza H, Knüppel S, Kühn T, Palli D, Bamia C, Boshuizen H, Bonet C, Overvad K, Johansson M, Travis R, Gunter MJ, Lund E, Dossus L, Elena-Herrmann B, Riboli E, Jenab M, Viallon V, Ferrari P. A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study. Mutagenesis 2015; 30:743-53. [PMID: 26130468 PMCID: PMC5909887 DOI: 10.1093/mutage/gev045] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Metabolomics is a potentially powerful tool for identification of biomarkers associated with lifestyle exposures and risk of various diseases. This is the rationale of the 'meeting-in-the-middle' concept, for which an analytical framework was developed in this study. In a nested case-control study on hepatocellular carcinoma (HCC) within the European Prospective Investigation into Cancer and nutrition (EPIC), serum (1)H nuclear magnetic resonance (NMR) spectra (800 MHz) were acquired for 114 cases and 222 matched controls. Through partial least square (PLS) analysis, 21 lifestyle variables (the 'predictors', including information on diet, anthropometry and clinical characteristics) were linked to a set of 285 metabolic variables (the 'responses'). The three resulting scores were related to HCC risk by means of conditional logistic regressions. The first PLS factor was not associated with HCC risk. The second PLS metabolomic factor was positively associated with tyrosine and glucose, and was related to a significantly increased HCC risk with OR = 1.11 (95% CI: 1.02, 1.22, P = 0.02) for a 1SD change in the responses score, and a similar association was found for the corresponding lifestyle component of the factor. The third PLS lifestyle factor was associated with lifetime alcohol consumption, hepatitis and smoking, and had negative loadings on vegetables intake. Its metabolomic counterpart displayed positive loadings on ethanol, glutamate and phenylalanine. These factors were positively and statistically significantly associated with HCC risk, with 1.37 (1.05, 1.79, P = 0.02) and 1.22 (1.04, 1.44, P = 0.01), respectively. Evidence of mediation was found in both the second and third PLS factors, where the metabolomic signals mediated the relation between the lifestyle component and HCC outcome. This study devised a way to bridge lifestyle variables to HCC risk through NMR metabolomics data. This implementation of the 'meeting-in-the-middle' approach finds natural applications in settings characterised by high-dimensional data, increasingly frequent in the omics generation.
Collapse
Affiliation(s)
- Nada Assi
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Anne Fages
- Centre de RMN à Très Hauts Champs, Institut des Sciences Analytiques (CNRS/ENS Lyon/UCB Lyon 1), Université de Lyon, 69100 Villeurbanne, France, Present address: Chemical Physics Department, Weizmann Institute of Science, Rehovot, Israel
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK
| | - Marc Chadeau-Hyam
- Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK
| | - Magdalena Stepien
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Talita Duarte-Salles
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Graham Byrnes
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Houda Boumaza
- Centre de RMN à Très Hauts Champs, Institut des Sciences Analytiques (CNRS/ENS Lyon/UCB Lyon 1), Université de Lyon, 69100 Villeurbanne, France
| | - Sven Knüppel
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, 14558 Nuthetal, Germany
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Domenico Palli
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy
| | - Christina Bamia
- Department of Hygiene, Epidemiology and Medical Statistics, WHO Collaborating Center for Food and Nutrition Policies, University of Athens Medical School, Athens, Greece
| | - Hendriek Boshuizen
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Catalina Bonet
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - Kim Overvad
- The Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark
| | - Mattias Johansson
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France, The Department for Biobank Research, Umeå University, Umeå, Sweden
| | - Ruth Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health University of Oxford, Oxford, UK
| | - Marc J Gunter
- Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK
| | - Eiliv Lund
- The Institute of Community Medicine, University of Tromsø, Tromsø, Norway
| | - Laure Dossus
- Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Lifestyle, Genes and Health: Integrative Trans-generational Epidemiology Team, Villejuif, France, Université Paris Sud, Villejuif, France
| | - Bénédicte Elena-Herrmann
- Centre de RMN à Très Hauts Champs, Institut des Sciences Analytiques (CNRS/ENS Lyon/UCB Lyon 1), Université de Lyon, 69100 Villeurbanne, France
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, UK
| | - Mazda Jenab
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | | | - Pietro Ferrari
- International Agency for Research in Cancer (IARC-WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France,
| |
Collapse
|
42
|
Ghantous A, Hernandez-Vargas H, Byrnes G, Dwyer T, Herceg Z. Characterising the epigenome as a key component of the fetal exposome in evaluating in utero exposures and childhood cancer risk. Mutagenesis 2015; 30:733-42. [PMID: 25724893 PMCID: PMC4757935 DOI: 10.1093/mutage/gev010] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Recent advances in laboratory sciences hold a promise for a 'leap forward' in understanding the aetiology of complex human diseases, notably cancer, potentially providing an evidence base for prevention. For example, remarkable advances in epigenomics have an important impact on our understanding of biological phenomena and importance of environmental stressors in complex diseases. Environmental and lifestyle factors are thought to be implicated in the development of a wide range of human cancers by eliciting changes in the epigenome. These changes, thus, represent attractive targets for biomarker discovery intended for the improvement of exposure and risk assessment, diagnosis and prognosis and provision of short-term outcomes in intervention studies. The epigenome can be viewed as an interface between the genome and the environment; therefore, aberrant epigenetic events associated with environmental exposures are likely to play an important role in the onset and progression of different human diseases. The advent of powerful technologies for analysing epigenetic patterns in both cancer tissues and normal cells holds promise that the next few years will be fundamental for the identification of critical cancer- and exposure-associated epigenetic changes and for their evaluation as new generation of biomarkers. Here, we discuss new opportunities in the current age of 'omics' technologies for studies with prospective design and associated biospecimens that represent exciting potential for characterising the epigenome as a key component of the fetal exposome and for understanding causal pathways and robust predictors of cancer risk and associated environmental determinants during in utero life. Such studies should improve our knowledge concerning the aetiology of childhood cancer and identify both novel biomarkers and clues to causation, thus, providing an evidence base for cancer prevention.
Collapse
Affiliation(s)
- Akram Ghantous
- Epigenetics and
- Biostatistics Groups, International Agency for Research on Cancer (IARC), 150 rue Albert-Thomas, F-69008 Lyon, France
- The George Institute for Global Health and Nuffield Department of Population Health, Oxford Martin School | University of Oxford, 34 Broad Street Oxford OX1 3BD, UK
| | - Hector Hernandez-Vargas
- Epigenetics and
- Biostatistics Groups, International Agency for Research on Cancer (IARC), 150 rue Albert-Thomas, F-69008 Lyon, France
- The George Institute for Global Health and Nuffield Department of Population Health, Oxford Martin School | University of Oxford, 34 Broad Street Oxford OX1 3BD, UK
| | - Graham Byrnes
- Biostatistics Groups, International Agency for Research on Cancer (IARC), 150 rue Albert-Thomas, F-69008 Lyon, France
| | - Terence Dwyer
- The George Institute for Global Health and Nuffield Department of Population Health, Oxford Martin School | University of Oxford, 34 Broad Street Oxford OX1 3BD, UK
| | - Zdenko Herceg
- *To whom correspondence should be addressed. Tel: +33-4-72 73 83 98; Fax: +33-4-72 73 83 29; E-mail:
| |
Collapse
|
43
|
Pertesi M, Galia P, Nazaret N, Vallée M, Garderet L, Leleu X, Avet-Loiseau H, Foll M, Byrnes G, Lachuer J, McKay JD, Dumontet C. Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. PLoS One 2015; 10:e0136505. [PMID: 26352266 PMCID: PMC4564105 DOI: 10.1371/journal.pone.0136505] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 08/04/2015] [Indexed: 12/30/2022] Open
Abstract
The MYD88 L265P is a recurrent somatic mutation in neoplastic cells from patients with Waldenström Macroglobulinemia (WM). We identified the MYD88 L265P mutation in three individuals from unrelated families, but its presence did not explain the disease segregation within these WM pedigrees. We observed the mutation in these three individuals at high allele fractions in DNA extracted from EBV-immortalized Lymphoblastoid cell lines established from peripheral blood (LCL), but at much lower allele fractions in DNA extracted directly from peripheral blood, suggesting that this mutation is present in a clonal cell subpopulation rather than of germ-line origin. Furthermore, we observed that the MYD88 L265P mutation is enriched in WM families, detected in 40.5% of patients with familial WM or MGUS (10/22 WM, 5/15 MGUS), compared to 3.5% of patients with familial MM or MGUS (0/72 MM, 4/41 MGUS) (p = 10-7). The mutant allele frequency increased with passages in vitro after immortalization with Epstein-Barr virus (EBV) consistent with the MYD88 L265P described gain-of-function proposed for this mutation. The MYD88 L265P mutation appears to be frequently present in circulating cells in patients with WM, and MGUS, and these cells are amenable to immortalization by EBV.
Collapse
Affiliation(s)
- Maroulio Pertesi
- Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France
| | - Perrine Galia
- Hospices Civils de Lyon, Pierre Bénite, France; INSERM 1052, CNRS 5286, CRCL, Lyon, France; University of Lyon, Lyon, France
- ProfilExpert, Lyon, France
| | | | - Maxime Vallée
- Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France
| | - Laurent Garderet
- INSERM, UMR_S 938, Proliferation and differentiation of stem cells, Paris, France; AP-HP, Hôpital Saint Antoine, Département d'hématologie et de thérapie cellulaire, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Paris, France
| | - Xavier Leleu
- Service des maladies du sang, Hopital Huriez CHRU, Lille, France; Centre de Recherche INSERM U837, Facteurs de persistance des cellules leucémiques, Institut pour la Recherche sur le Cancer (IRCL), Lille, France
| | - Hervé Avet-Loiseau
- Unité génomique du myélome, Institut Universitaire du Cancer de Toulouse—Oncopole, CRCT INSERM U1037, Toulouse, France
| | - Matthieu Foll
- Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France
| | - Graham Byrnes
- Biostatistics, International Agency for Research on Cancer, Lyon, France
| | | | - James D. McKay
- Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France
| | - Charles Dumontet
- Hospices Civils de Lyon, Pierre Bénite, France; INSERM 1052, CNRS 5286, CRCL, Lyon, France; University of Lyon, Lyon, France
- ProfilExpert, Lyon, France
| |
Collapse
|
44
|
Delahaye-Sourdeix M, Anantharaman D, Timofeeva MN, Gaborieau V, Chabrier A, Vallée MP, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Thakker NS, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Mates IN, Bencko V, Foretova L, Janout V, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Fernández Garrote L, Polesel J, Lener M, Jaworowska E, Lubiński J, Boccia S, Rajkumar T, Samant TA, Mahimkar MB, Matsuo K, Franceschi S, Byrnes G, Brennan P, McKay JD. A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer. J Natl Cancer Inst 2015; 107:djv037. [PMID: 25838448 PMCID: PMC4822523 DOI: 10.1093/jnci/djv037] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Revised: 09/05/2014] [Accepted: 01/29/2015] [Indexed: 01/07/2023] Open
Abstract
Deleterious BRCA2 genetic variants markedly increase risk of developing breast cancer. A rare truncating BRCA2 genetic variant, rs11571833 (K3326X), has been associated with a 2.5-fold risk of lung squamous cell carcinoma but only a modest 26% increase in breast cancer risk. We analyzed the association between BRCA2 SNP rs11571833 and upper aerodigestive tract (UADT) cancer risk with multivariable unconditional logistic regression adjusted by sex and combinations of study and country for 5942 UADT squamous cell carcinoma case patients and 8086 control patients from nine different studies. All statistical tests were two-sided. rs11571833 was associated with UADT cancers (odds ratio = 2.53, 95% confidence interval = 1.89 to 3.38, P = 3x10(-10)) and was present in European, Latin American, and Indian populations but extremely rare in Japanese populations. The association appeared more apparent in smokers (current or former) compared with never smokers (P het = .026). A robust association between a truncating BRCA2 variant and UADT cancer risk suggests that treatment strategies orientated towards BRCA2 mutations may warrant further investigation in UADT tumors.
Collapse
Affiliation(s)
- Manon Delahaye-Sourdeix
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Devasena Anantharaman
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Maria N Timofeeva
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Valérie Gaborieau
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Amélie Chabrier
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Maxime P Vallée
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Pagona Lagiou
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Ivana Holcátová
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Lorenzo Richiardi
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Kristina Kjaerheim
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Antonio Agudo
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Xavier Castellsagué
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Tatiana V Macfarlane
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Luigi Barzan
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Cristina Canova
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Nalin S Thakker
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - David I Conway
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Ariana Znaor
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Claire M Healy
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Wolfgang Ahrens
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - David Zaridze
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Neonilia Szeszenia-Dabrowska
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Jolanta Lissowska
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Eleonora Fabianova
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Ioan Nicolae Mates
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Vladimir Bencko
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Lenka Foretova
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Vladimir Janout
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Maria Paula Curado
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Sergio Koifman
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Ana Menezes
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Victor Wünsch-Filho
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - José Eluf-Neto
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Paolo Boffetta
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Leticia Fernández Garrote
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Jerry Polesel
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Marcin Lener
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Ewa Jaworowska
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Jan Lubiński
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Stefania Boccia
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Thangarajan Rajkumar
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Tanuja A Samant
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Manoj B Mahimkar
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Keitaro Matsuo
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Silvia Franceschi
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Graham Byrnes
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - Paul Brennan
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| | - James D McKay
- : Genetic Cancer Susceptibility Group (MDS, AC, MPV, JDM), Genetic Epidemiology Group (DA, MNT, VG, PBr), Infections and Cancer Epidemiology Group (SF), and Biostatistics Group (GB), International Agency for Research on Cancer, Lyon, France; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council, Human Genetics Unit, Edinburgh, UK (MNT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece (PL); Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (IH, VB); University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy (LR); Cancer Registry of Norway, Oslo, Norway (KK); Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain (AA, XC); CIBER Epidemiología y Salud Pública, Spain (XC); School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK (TVM); General Hospital of Pordenone, Pordenone, Italy (LB); Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy (CC); MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, UK (CC); University of Manchester, School of Dentistry, Manchester, UK (NST); University of Glasgow Dental School, Glasgow, Scotland, UK (DIC); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Trinity College School of Dental Science, Dublin, Ireland (CMH); Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany (WA); Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany (WA); Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation (DZ); Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland (NSD); Department of Ca
| |
Collapse
|
45
|
Delahaye-Sourdeix M, Oliver J, Timofeeva MN, Gaborieau V, Johansson M, Chabrier A, Wozniak MB, Brenner DR, Vallée MP, Anantharaman D, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Thakker NS, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Mates IN, Bencko V, Foretova L, Janout V, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Garrote LF, Serraino D, Lener M, Jaworowska E, Lubiński J, Boccia S, Rajkumar T, Samant TA, Mahimkar MB, Matsuo K, Franceschi S, Byrnes G, Brennan P, McKay JD. The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract. PLoS One 2015; 10:e0117639. [PMID: 25793373 PMCID: PMC4368781 DOI: 10.1371/journal.pone.0117639] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 12/29/2014] [Indexed: 11/18/2022] Open
Abstract
Genetic variants located within the 12p13.33/RAD52 locus have been associated with lung squamous cell carcinoma (LUSC). Here, within 5,947 UADT cancers and 7,789 controls from 9 different studies, we found rs10849605, a common intronic variant in RAD52, to be also associated with upper aerodigestive tract (UADT) squamous cell carcinoma cases (OR = 1.09, 95% CI: 1.04-1.15, p = 6x10(-4)). We additionally identified rs10849605 as a RAD52 cis-eQTL inUADT(p = 1x10(-3)) and LUSC (p = 9x10(-4)) tumours, with the UADT/LUSC risk allele correlated with increased RAD52 expression levels. The 12p13.33 locus, encompassing rs10849605/RAD52, was identified as a significant somatic focal copy number amplification in UADT(n = 374, q-value = 0.075) and LUSC (n = 464, q-value = 0.007) tumors and correlated with higher RAD52 tumor expression levels (p = 6x10(-48) and p = 3x10(-29) in UADT and LUSC, respectively). In combination, these results implicate increased RAD52 expression in both genetic susceptibility and tumorigenesis of UADT and LUSC tumors.
Collapse
Affiliation(s)
- Manon Delahaye-Sourdeix
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Javier Oliver
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Maria N. Timofeeva
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
- Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council (MRC) Human Genetics Unit, Edinburgh, United Kingdom
| | - Valérie Gaborieau
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Mattias Johansson
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Amélie Chabrier
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Magdalena B. Wozniak
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Darren R. Brenner
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Maxime P. Vallée
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Devasena Anantharaman
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece
| | - Ivana Holcátová
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lorenzo Richiardi
- University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy
| | | | - Antonio Agudo
- Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain
| | - Xavier Castellsagué
- Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | | | | | - Cristina Canova
- Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
- MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
| | - Nalin S. Thakker
- University of Manchester, School of Dentistry, Manchester, United Kingdom
| | - David I. Conway
- University of Glasgow Dental School, Glasgow, Scotland, United Kingdom
| | - Ariana Znaor
- Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia
| | | | - Wolfgang Ahrens
- Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany
- Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany
| | - David Zaridze
- Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation
| | | | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | | | - Ioan Nicolae Mates
- Saint Mary General and Esophageal Surgery Clinic, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Vladimir Bencko
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lenka Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
| | | | | | - Sergio Koifman
- National School of Public Health/FIOCRUZ, Rio de Janeiro, Brazil
| | - Ana Menezes
- Universidade Federal de Pelotas, Pelotas, Brazil
| | | | | | - Paolo Boffetta
- The Tisch Cancer Institute Mount Sinai School of Medicine, New York, NY, United States of America
| | | | - Diego Serraino
- Centro di Riferimento Oncologico, IRCSS, Unit of Epidemiology and Biostatistics, Aviano, Italy
| | - Marcin Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Ewa Jaworowska
- Department of Otolaryngology and Laryngological Oncology, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Stefania Boccia
- Institute of Public Health, Section of Hygiene, Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | - Tanuja A. Samant
- Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Manoj B. Mahimkar
- Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Keitaro Matsuo
- Department of Health Promotion, Division of Oral Pathology, Kyushu Dental University, Kitakyushu, Japan
| | - Silvia Franceschi
- Infections and Cancer Epidemiology group (ICE), International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- Biostatistics group (BST), International Agency for Research on Cancer (IARC), Lyon, France
| | - Paul Brennan
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - James D. McKay
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
46
|
Zamora-Ros R, Rinaldi S, Biessy C, Tjønneland A, Halkjaer J, Fournier A, Boutron-Ruault MC, Mesrine S, Tikk K, Fortner RT, Boeing H, Förster J, Trichopoulou A, Trichopoulos D, Papatesta EM, Masala G, Tagliabue G, Panico S, Tumino R, Polidoro S, Peeters PHM, Bueno-de-Mesquita HB, Weiderpass E, Lund E, Argüelles M, Agudo A, Molina-Montes E, Navarro C, Barricarte A, Larrañaga N, Manjer J, Almquist M, Sandström M, Hennings J, Tsilidis KK, Schmidt JA, Khaw KT, Wareham NJ, Romieu I, Byrnes G, Gunter MJ, Riboli E, Franceschi S. Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer 2015; 136:1218-27. [PMID: 25041790 DOI: 10.1002/ijc.29067] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 06/05/2014] [Accepted: 06/11/2014] [Indexed: 02/02/2023]
Abstract
Differentiated thyroid carcinoma (TC) is threefold more common in women than in men and, therefore, a role of female hormones in the etiology of differentiated TC has been suggested. We assessed these hypotheses in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Among 345,157 women (mean age 51) followed for an average of 11 years, 508 differentiated TC cases were identified. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. No significant associations were observed between differentiated TC risk and number of pregnancies, breast feeding, menopausal status, and age at menarche and at menopause. Significant associations were found with history of infertility problems (HR 1.70; 95% CI 1.12-2.60), a recent pregnancy (HR for ≤ 5 vs. >5 years before recruitment 3.87; 95% CI 1.43-10.46), menopause type (HR for surgical vs. natural menopause: 2.16; 95% CI 1.41-3.31), oral contraceptive (OC) use at recruitment (HR: 0.48; 95% CI 0.25-0.92) and duration of OC use (HR for ≥ 9 vs. ≤ 1 year: 0.66; 95% CI: 0.50-0.89). An increased risk was also found with hormone replacement therapy use at recruitment (HR = 1.30, 95% CI 1.02-1.67), but this was not significant after adjustment for type of menopause (HR = 1.22, 95% CI 0.95-1.57). Overall, our findings do not support a strong role of reproductive and menstrual factors, and female hormone use in the etiology of differentiated TC. The few observed associations may be real or accounted for by increased surveillance in women who had infertility problems, recent pregnancies or underwent surgical menopause.
Collapse
Affiliation(s)
- Raul Zamora-Ros
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, Ferlay J, Miranda JJ, Romieu I, Dikshit R, Forman D, Soerjomataram I. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015; 16:36-46. [PMID: 25467404 PMCID: PMC4314462 DOI: 10.1016/s1470-2045(14)71123-4] [Citation(s) in RCA: 595] [Impact Index Per Article: 66.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND High body-mass index (BMI; defined as 25 kg/m(2) or greater) is associated with increased risk of cancer. To inform public health policy and future research, we estimated the global burden of cancer attributable to high BMI in 2012. METHODS In this population-based study, we derived population attributable fractions (PAFs) using relative risks and BMI estimates in adults by age, sex, and country. Assuming a 10-year lag-period between high BMI and cancer occurrence, we calculated PAFs using BMI estimates from 2002 and used GLOBOCAN2012 data to estimate numbers of new cancer cases attributable to high BMI. We also calculated the proportion of cancers that were potentially avoidable had populations maintained their mean BMIs recorded in 1982. We did secondary analyses to test the model and to estimate the effects of hormone replacement therapy (HRT) use and smoking. FINDINGS Worldwide, we estimate that 481,000 or 3.6% of all new cancer cases in adults (aged 30 years and older after the 10-year lag period) in 2012 were attributable to high BMI. PAFs were greater in women than in men (5.4% vs 1.9%). The burden of attributable cases was higher in countries with very high and high human development indices (HDIs; PAF 5.3% and 4.8%, respectively) than in those with moderate (1.6%) and low HDIs (1.0%). Corpus uteri, postmenopausal breast, and colon cancers accounted for 63.6% of cancers attributable to high BMI. A quarter (about 118,000) of the cancer cases related to high BMI in 2012 could be attributed to the increase in BMI since 1982. INTERPRETATION These findings emphasise the need for a global effort to abate the increasing numbers of people with high BMI. Assuming that the association between high BMI and cancer is causal, the continuation of current patterns of population weight gain will lead to continuing increases in the future burden of cancer. FUNDING World Cancer Research Fund International, European Commission (Marie Curie Intra-European Fellowship), Australian National Health and Medical Research Council, and US National Institutes of Health.
Collapse
Affiliation(s)
- Melina Arnold
- Section of Cancer Surveillance, International Agency for
Research on Cancer, Lyon, France
| | - Nirmala Pandeya
- School of Population Health, The University of Queensland,
Brisbane, Queensland, Australia
| | - Graham Byrnes
- Biostatistics Group, International Agency for Research on
Cancer, Lyon, France
| | - Prof Andrew G Renehan
- Faculty Institute of Cancer Sciences, University of Manchester,
Manchester Academic Health Science Centre, Manchester, United Kingdom
| | - Gretchen A Stevens
- Department of Health Statistics and Information Systems, World
Health Organization, Geneva, Switzerland
| | - Prof Majid Ezzati
- MRC-PHE Centre for Environment and Health, Imperial College
London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public
Health, Imperial College London, London, United Kingdom
| | - Jacques Ferlay
- Section of Cancer Surveillance, International Agency for
Research on Cancer, Lyon, France
| | - J. Jaime Miranda
- CRONICAS Centre of Excellence in Chronic Diseases, and School of
Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Isabelle Romieu
- Nutrition and Metabolism Section/Epidemiology Group,
International Agency for Research on Cancer, Lyon, France
| | - Rajesh Dikshit
- Department of Epidemiology, Tata Memorial Hospital, Mumbai,
Maharashtra, India
| | - David Forman
- Section of Cancer Surveillance, International Agency for
Research on Cancer, Lyon, France
| | - Isabelle Soerjomataram
- Section of Cancer Surveillance, International Agency for
Research on Cancer, Lyon, France
| |
Collapse
|
48
|
McCormack V, Peto J, Byrnes G, Straif K, Boffetta P. Erratum: Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer 2014. [PMCID: PMC4264459 DOI: 10.1038/bjc.2014.616] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
49
|
Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 2014; 5:5135. [PMID: 25351205 DOI: 10.1038/ncomms6135] [Citation(s) in RCA: 132] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Accepted: 09/03/2014] [Indexed: 12/31/2022] Open
Abstract
The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and genes encoding FAT cadherins. Furthermore, a large majority of patients from Romania have an unexpected high frequency of A:T>T:A transversions, consistent with exposure to aristolochic acid (AA). These results show that the processes underlying ccRCC tumorigenesis may vary in different populations and suggest that AA may be an important ccRCC carcinogen in Romania, a finding with major public health implications.
Collapse
Affiliation(s)
- Ghislaine Scelo
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Yasser Riazalhosseini
- 1] Department of Human Genetics, McGill University, 1205 Dr Penfield Avenue, Montreal, Quebec, Canada H3A 1B1 [2] McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Liliana Greger
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK
| | - Louis Letourneau
- McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Mar Gonzàlez-Porta
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK
| | - Magdalena B Wozniak
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Mathieu Bourgey
- McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Patricia Harnden
- Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds LS9 7TF, UK
| | - Lars Egevad
- Department of Pathology, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Sharon M Jackson
- Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds LS9 7TF, UK
| | - Mehran Karimzadeh
- 1] Department of Human Genetics, McGill University, 1205 Dr Penfield Avenue, Montreal, Quebec, Canada H3A 1B1 [2] McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Madeleine Arseneault
- 1] Department of Human Genetics, McGill University, 1205 Dr Penfield Avenue, Montreal, Quebec, Canada H3A 1B1 [2] McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Pierre Lepage
- McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Alexandre How-Kit
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Antoine Daunay
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Victor Renault
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Hélène Blanché
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Emmanuel Tubacher
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Jeremy Sehmoun
- Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France
| | - Juris Viksna
- Institute of Mathematics and Computer Science, University of Latvia, 29 Rainis Boulevard, Riga LV-1459, Latvia
| | - Edgars Celms
- Institute of Mathematics and Computer Science, University of Latvia, 29 Rainis Boulevard, Riga LV-1459, Latvia
| | - Martins Opmanis
- Institute of Mathematics and Computer Science, University of Latvia, 29 Rainis Boulevard, Riga LV-1459, Latvia
| | - Andris Zarins
- Institute of Mathematics and Computer Science, University of Latvia, 29 Rainis Boulevard, Riga LV-1459, Latvia
| | - Naveen S Vasudev
- Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds LS9 7TF, UK
| | - Morag Seywright
- Department of Pathology, The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, UK
| | - Behnoush Abedi-Ardekani
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Christine Carreira
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Peter J Selby
- Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds LS9 7TF, UK
| | - Jon J Cartledge
- Leeds Teaching Hospitals NHS Trust, Pyrah Department of Urology, Lincoln Wing, St James's University Hospital, Leeds LS9 7TF, UK
| | - Graham Byrnes
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Jiri Zavadil
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Jing Su
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK
| | - Ivana Holcatova
- First Faculty of Medicine, Institute of Hygiene and Epidemiology, Charles University in Prague, Studničkova 7, Praha 2, 128 00 Prague, Czech Republic
| | - Antonin Brisuda
- University Hospital Motol, V Úvalu 84, 150 06 Prague, Czech Republic
| | - David Zaridze
- Russian N.N. Blokhin Cancer Research Centre, Kashirskoye shosse 24, Moscow 115478, Russian Federation
| | - Anush Moukeria
- Russian N.N. Blokhin Cancer Research Centre, Kashirskoye shosse 24, Moscow 115478, Russian Federation
| | - Lenka Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Zluty Kopec 7, 656 53 Brno, Czech Republic
| | - Marie Navratilova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Zluty Kopec 7, 656 53 Brno, Czech Republic
| | - Dana Mates
- National Institute of Public Health, Dr Leonte Anastasievici 1-3, sector 5, Bucuresti 050463, Romania
| | - Viorel Jinga
- Carol Davila University of Medicine and Pharmacy, Th. Burghele Hospital, 20 Panduri Street, 050659 Bucharest, Romania
| | - Artem Artemov
- Centre 'Bioengineering', The Russian Academy of Sciences, Moscow 117312, Russian Federation
| | - Artem Nedoluzhko
- National Research Centre 'Kurchatov Institute', 1 Akademika Kurchatova pl., Moscow 123182, Russia
| | - Alexander Mazur
- Centre 'Bioengineering', The Russian Academy of Sciences, Moscow 117312, Russian Federation
| | - Sergey Rastorguev
- National Research Centre 'Kurchatov Institute', 1 Akademika Kurchatova pl., Moscow 123182, Russia
| | - Eugenia Boulygina
- National Research Centre 'Kurchatov Institute', 1 Akademika Kurchatova pl., Moscow 123182, Russia
| | - Simon Heath
- Centro Nacional de Análisis Genómico, Baldiri Reixac, 4, Barcleona Science Park - Tower I, 08028 Barcelona, Spain
| | - Marta Gut
- Centro Nacional de Análisis Genómico, Baldiri Reixac, 4, Barcleona Science Park - Tower I, 08028 Barcelona, Spain
| | - Marie-Therese Bihoreau
- Centre National de Génotypage, CEA - Institute de Génomique, 2 rue Gaston Crémieux, 91000 Evry, France
| | - Doris Lechner
- Centre National de Génotypage, CEA - Institute de Génomique, 2 rue Gaston Crémieux, 91000 Evry, France
| | - Mario Foglio
- Centre National de Génotypage, CEA - Institute de Génomique, 2 rue Gaston Crémieux, 91000 Evry, France
| | - Ivo G Gut
- Centro Nacional de Análisis Genómico, Baldiri Reixac, 4, Barcleona Science Park - Tower I, 08028 Barcelona, Spain
| | - Konstantin Skryabin
- 1] Centre 'Bioengineering', The Russian Academy of Sciences, Moscow 117312, Russian Federation [2] National Research Centre 'Kurchatov Institute', 1 Akademika Kurchatova pl., Moscow 123182, Russia
| | - Egor Prokhortchouk
- 1] Centre 'Bioengineering', The Russian Academy of Sciences, Moscow 117312, Russian Federation [2] National Research Centre 'Kurchatov Institute', 1 Akademika Kurchatova pl., Moscow 123182, Russia
| | - Anne Cambon-Thomsen
- Faculty of Medicine, Institut National de la Santé et de la Recherche Medicale (INSERM) and University Toulouse III-Paul Sabatier, UMR 1027, 37 allées Jules Guesde, 31000 Toulouse, France
| | - Johan Rung
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK
| | - Guillaume Bourque
- 1] Department of Human Genetics, McGill University, 1205 Dr Penfield Avenue, Montreal, Quebec, Canada H3A 1B1 [2] McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, Quebec, Canada H3A 0G1
| | - Paul Brennan
- International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008 Lyon, France
| | - Jörg Tost
- Centre National de Génotypage, CEA - Institute de Génomique, 2 rue Gaston Crémieux, 91000 Evry, France
| | - Rosamonde E Banks
- Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds LS9 7TF, UK
| | - Alvis Brazma
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK
| | - G Mark Lathrop
- 1] Department of Human Genetics, McGill University, 1205 Dr Penfield Avenue, Montreal, Quebec, Canada H3A 1B1 [2] Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, 27 rue Juliette Dodu, 75010 Paris, France [3] Centre National de Génotypage, CEA - Institute de Génomique, 2 rue Gaston Crémieux, 91000 Evry, France
| |
Collapse
|
50
|
Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun 2014; 5:3856. [PMID: 24920014 PMCID: PMC4055950 DOI: 10.1038/ncomms4856] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Accepted: 04/11/2014] [Indexed: 12/20/2022] Open
Abstract
Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI) = 0.76-0.86, P(combined) = 3.5 × 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regulator of B- and T-cell lineage commitment known to be involved in HL pathogenesis. This meta-analysis also notes associations between previously published loci at 2p16, 5q31, 6p31, 8q24 and 10p14 and HL subtypes. We conclude that our data suggest a link between the 19p13.3 locus, including TCF3, and HL risk.
Collapse
Affiliation(s)
- W Cozen
- 1] USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA [2]
| | - M N Timofeeva
- 1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2] Institute of Genetics and Molecular Medicine, University of Edinburgh, EH4 2XU Edinburgh, UK [3]
| | | | - A Diepstra
- 1] University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands [2]
| | - D Hazelett
- 1] USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA [2]
| | - M Delahaye-Sourdeix
- 1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2]
| | - C K Edlund
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - L Franke
- University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
| | - K Rostgaard
- Statens Serum Institut, DK-2300 Copenhagen, Denmark
| | - D J Van Den Berg
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - V K Cortessis
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - K E Smedby
- Karolinska Institutet and Karolinska University Hospital, S-221 00 Stockholm, Sweden
| | - S L Glaser
- Cancer Prevention Institute of California, Fremont, California 94538, USA
| | - H-J Westra
- University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
| | - L L Robison
- St Jude Children's Hospital, Cordova, Tennessee 38105, USA
| | - T M Mack
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - H Ghesquieres
- Centre Léon Bérard, UMR CNRS 5239-Université Lyon 1, 69008 Lyon, France
| | - A E Hwang
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - A Nieters
- University Medical Centre Freiburg, D-79085 Freiburg, Germany
| | - S de Sanjose
- IDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain
| | | | - N Becker
- German Cancer Research Centre, D-69120 Heidelberg, Germany
| | - M Maynadie
- CHU de Dijon, EA 4184, University of Burgundy, 21070 Dijon, France
| | - L Foretova
- Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
| | - E Roman
- University of York, YO10 5DD York, UK
| | - Y Benavente
- IDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain
| | - K A Rand
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - B N Nathwani
- City of Hope National Medical Center, Duarte, California 91010, USA
| | | | - A Staines
- School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland
| | - P Boffetta
- Icahn School of Medicine at Mount Sinai, New York City, New York 10029-6574, USA
| | - B K Link
- University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
| | - L Kiemeney
- Radboud University Nijmegen Medical Centre, 6500HB Nijmegen, The Netherlands
| | - S M Ansell
- Mayo Clinic, Rochester, Minnesota 55905, USA
| | - S Bhatia
- City of Hope National Medical Center, Duarte, California 91010, USA
| | - L C Strong
- MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
| | - P Galan
- INSERM U557 (UMR Inserm; INRA; CNAM, Université Paris 13), 93017 Paris, France
| | - L Vatten
- Norwegian University of Science and Technology, NO-7491 Trondheim, Norway
| | | | - E J Duell
- IDIBELL Institut Català d'Oncologia, 8907 Barcelona, Spain
| | - A Lake
- MRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK
| | - R N Veenstra
- University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
| | - L Visser
- University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
| | - Y Liu
- University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
| | - K Y Urayama
- Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo 104-0044, Japan
| | - D Montgomery
- MRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK
| | - V Gaborieau
- International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - L M Weiss
- Clarient Pathology Services, Aliso Viejo, California 92656, USA
| | - G Byrnes
- International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - M Lathrop
- Genome Quebec, Montreal, Canada H3A 0G1
| | - P Cocco
- Institute of Occupational Health, University of Cagliari, Monserrato, 09042 Cagliari, Italy
| | - T Best
- The University of Chicago, Chicago, Illinois 60637-5415, USA
| | - A D Skol
- The University of Chicago, Chicago, Illinois 60637-5415, USA
| | - H-O Adami
- 1] Karolinska Institutet and Karolinska University Hospital, S-221 00 Stockholm, Sweden [2] Harvard University School of Public Health, Boston, Massachusetts 02115, USA
| | - M Melbye
- Statens Serum Institut, DK-2300 Copenhagen, Denmark
| | - J R Cerhan
- Mayo Clinic, Rochester, Minnesota 55905, USA
| | - A Gallagher
- MRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK
| | - G M Taylor
- School of Cancer Sciences, University of Manchester, St Mary's Hospital, M13 0JH Manchester, UK
| | - S L Slager
- Mayo Clinic, Rochester, Minnesota 55905, USA
| | - P Brennan
- International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - G A Coetzee
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - D V Conti
- USC Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9175, USA
| | - K Onel
- 1] The University of Chicago, Chicago, Illinois 60637-5415, USA [2]
| | - R F Jarrett
- 1] MRC University of Glasgow Centre for Virus Research, Garscube Estate, University of Glasgow, G12 8QQ Glasgow, Scotland, UK [2]
| | - H Hjalgrim
- 1] Statens Serum Institut, DK-2300 Copenhagen, Denmark [2]
| | - A van den Berg
- 1] University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands [2]
| | - J D McKay
- 1] International Agency for Research on Cancer (IARC), 69372 Lyon, France [2]
| |
Collapse
|